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 This thesis describes the synthesis of several natural products, isolated from the 
marine sponges of the genus Leucetta, which have demonstrated an ability to influence a 
diverse range of biological processes, including the potential to inhibit important cancer 
signaling pathways.  To understand this activity in more detail, the synthesis of 
naamidine A, related natural products and analogues was designed and implemented for 
the characterization of target binding in vitro and in vivo. 
 In addition, the expansion of synthetic application used towards these natural 
products is described.  The resulting methodology was used for the synthesis of 2-thio 
and 2-oxoimidazoles.   
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 STANDARD LIST OF ABBREVIATIONS 
 
Å       Ångström 
Ac       acetyl 
AcOH       acetic acid 
AgOAc     silver acetate 
Bn      benzyl 
Boc      tert-butylcarbamate 
BPS       tert-butyldiphenylsilyl 
BSA      N,O-bis (trimethylsilyl)acetamide 
n-Bu       butyl 
t-Bu       tert-butyl 
n-BuLi      n-butyllithium 
t-BuLi      tert-butyllithium 
°C       degrees Celsius 
calcd       calculated 
CDCl3       deuterated chloroform 
CHCl3       chloroform 
CH2Cl2      dichloromethane 
CI       chemical ionization 
d       day(s); doublet (spectral) 
DAST      diethylaminosulfur trifluoride 

d.r.       diastereomeric ratio 
DEPT distortionless enhancement by polarization 
transfer 
 
DIBAL      diisobutylaluminun hydride 
DIPEA      diisopropylethylamine 
DMAP      4-dimethylaminopyridine 
DMF       dimethylformamide 
DMSO      dimethyl sulfoxide 
EDTA      ethylenediaminetetraacetic acid 
EI       electron ionization 
Et       ethyl 
EtOH       ethanol 
Et2O       diethylether 
EtOAc      ethyl acetate 
Et3N       triethylamine 
g       gram(s) 
GC       gas chromatography 
h       hour(s) 
HRMS      high-resolution mass spectrum 
Hz       hertz 
IC50       50% inhibitory concentration 
IR       infrared 
J       coupling constant (in NMR) 
K2CO3      potassium carbonate 

KOtBu      potassium tert-butoxide 
La(OTf)     lanthanum trifluoromethanesulfonate 
LDA       lithium diisopropyl amide 
LRMS      low-resolution mass spectrum 
LTMP      Lithium 2,2,6,6-tetramethylpiperidide 
M       molarity, mol/L; mega 
Me       methyl 
MeCN      acetonitrile 
MeOH      methanol 
MgSO4      magnesium sulfate 
MHz       megahertz 
min       minute(s) 
mL       milliliter 
mol       mole(s) 
MOM      methoxymethyl ether 
mp       melting point 
MS       mass spectrometry; molecular sieves 
m/z       mass to charge ratio (in mass spectrometry) 
NaBH4      sodium borohydride 
NaHCO3      sodium bicarbonate 
NaHSO4      sodiumhydrogen sulfate 
Na2SO4      sodium sulfate 
NBS      N-bromosuccinimide 
NH4Cl      ammonium chloride 

NMO       N-methylmorpholine-N-oxide 
NMR       nuclear magnetic resonance 
Ph       phenyl 
PMB       para-methoxybenzyl 
ppm       parts per million (in NMR) 
iPr       isopropyl 
iPr2NH      diisopropylamine 
iPr2NEt     diisopropylethylamine 
py       pyridine 
q       quartet (spectral) 
quant       quantitative 
Rf       retention factor (in chromatography) 
rt       room temperature 
s       singlet (spectral); second(s) 
t       triplet (spectral) 
TBAF      tetra-n-butylammonium fluoride 
TBS      tributylsilyl 
Tf       trifluoromethanesulfonoyl, triflate 
TFA       trifluoroacetic acid 
TFAA      trifluoroacetic anhydride 
TfOH       trifluoromethanesulfonic acid 
THF       tetrahydrofuran 
TLC       thin layer chromatography 

TMS       trimethylsilyl, tetramethylsilane 
TMSOTf      trimethylsilyl trifluoromethanesulfonate 
Trs      trisyl 
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2-AMINOIMIDAZOLE NATURAL PRODUCTS 
 
Introduction 
Marine organisms are among the most promising sources for compounds with 
biological activity.1  Natural products from the Leucetta genus of marine organisms have 
been isolated since the late 1980s and have been found to contain several related 
heterocyclic alkaloid scaffolds.2  This family of alkaloids (Figure 1.1) is characterized by 
the presence of a 2-aminoimidazole moiety, which is substituted at various positions 
around the heterocycle and contains at least one benzylic fragment.3  In a review 
published by Looper and coworkers,4 it was suggested that the variations in the 2-
aminoimidazole alkaloid skeleton could be roughly characterized into four categories 
related by successive biosynthetic condensation/oxidation reactions (Figure 1.1).  
Several isolated 2-aminoimidazole natural products from each category have 
displayed a diverse range of biological activity.  Naamine D (1.1), for example, was 
shown to be a modest competitive inhibitor of inducible nitric oxide synthase (iNOS), 
demonstrating a 50% reduction in nitric oxide production at 1.0 mM5 (Figure 1.2).  
Kealiinine A (1.3) is shown to be toxic to brine shrimp (LD50 = 20 μg/mL), while 
Leucosolenamine A (1.4) is cytotoxic against the murine colon adenocarcinoma C-38 

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cell line. The category II 2-aminoimidazole naamidine A (1.2), in particular has served as 
a lead compound of interest for the Looper research group and has provided a sensible 
starting point for preliminary synthetic efforts and biological studies. 
 Naamidine A was isolated in 1987 from Leucetta chagosensis.6  It was not until a 
decade later that biological studies correlated naamidine A with programmed cell death, 
or cellular apoptosis.  Malfunctions of apoptosis are prevalent among several diseases 
including cancer, and so naamidine A has been increasingly viewed as a potential 
antitumor agent.7  Initial studies by Ireland and co-workers showed that naamidine A was 
an inhibitor of the epidermal growth factor (EGF) receptor signaling, important in the 
development of some human tumors.7  When tested in a mouse xenograft model, 
naamidine A inhibited tumor growth by 87% at a dose of 25 mg/kg.  Naamidine A also 
lowered anti-mitogenic activity compared to similar category II natural products 
isonaamidine B (1.5) and isonaamidine C (1.6) (Figure 1.3) suggesting that naamidine A 
was selectively antagonizing the EGF signaling cascade.  Ireland also showed that 
naamidine A was mildly cytotoxic towards the HCT116 human colon tumor cell line.  
Additional studies showed that an activator of the Ras-MAP kinase signaling pathway 
resulting in constant extracellular signal regulated kinases 1/2 (ERK1/2) activation 
leading to a G1 cell cycle arrest.8  In 2009, Ireland later showed that naamidine A induces 
apoptosis by disruption of the mitochondrial membrane potential.  This interruption leads 
to the activation of the pro-apoptotic factors caspases 3, 8 and 9.9  The phenotypic 
response of naamidine A has garnered much attention for its antiproliferative effects on 
tumors.  However, what has yet to be elucidated is the mechanism of action by which 
naamidine A induces these responses. 

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Previous Synthetic Strategies 
The structural novelty of this highly substituted 2-aminoimidazole core and the 
biological activity associated with naamidine A have attracted synthetic interest.  
Interestingly, the current reported syntheses of naamidine A all employ unique strategies, 
yet rely on the synthesis of naamidine A’s presumed biosynthetic precursor, naamine A. 
 
Ohta’s synthesis 
Ohta has synthesized several members of the naamine and naamidine family.10   
In 2000, he began the synthesis of naamidine A with 1-methyl-2-phenylthio-1H-
imidazole (1.7), and then sequentially functionalized the imidazole ring through a series 
of selective lithiation/addition reactions (Figure 1.4).  Thiophenyl substituted imidazole 
1.7 was first selectively lithiated with t-BuLi and followed by the addition of MOM 
protected p-hydroxybenzaldehyde to give alcohol 1.8.  The newly formed hydroxyl group 
was then protected as its TBS-ether.  Next, bromination of the C-4 of the imidazole ring 
was accomplished to give 1.9.  A lithium-halogen exchange using t-BuLi was then 
followed by the addition of p-methoxybenzaldehyde to give tetrasubstituted imidazole 
1.10 as an inconsequential 1:1 mixture of diastereomers.  Desilylation of the TBS-ether 
with TBAF in THF gave diol 1.11.  Reduction of the thiophenol group with nickel (II) 
chloride/NaBH4 gave 1.12 with a significant amount of the mono-deoxygenated products 
1.13.  Deoxygenation of the carbinols with zinc powder in concentrated HCl/AcOH then 
gave the deprotected phenol, which subsequently was reprotected as its TBS-silyl ether to 
give 1.14.   
Selective bromination at the 2-position of the imidazole with NBS gave the 

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bromide which was followed by lithium/halogen exchange then addition to trisyl azide to 
give 2-azidoimidazole 1.15.  Hydrogenolysis of the azide yielded the 2-aminoimidazole.  
Deprotection of the phenolic TBS ether with TBAF gave the natural product naamine A 
(1.16).  Conversion of 1.16 to naamidine A (1.2) was accomplished in 44% yield by the 
selective condensation of 1-methylparabanic acid in the presence of TMSCl/Et3N.   




The second total synthesis of naamidine A was accomplished by Watson in 2006.2  
Watson began the synthesis of naamidine A with a selective N-methylation of the 
commercially available Boc protected amino acid 1.17 (Figure 1.5).  Using conditions 
developed by Benoiton, Watson observed no methyl ester formation, forming exclusively 
the acid 1.18.  Methylation of the amine was essential to install the required 
regiochemistry in the ring.  Formation of the Weinreb amide 1.19 was accomplished by 
in situ formation of the acid fluoride followed by the addition of N,O-
dimethylhydroxyamine. Addition of magnesiated p-methoxybenzyl chloride gave the 
ketone 1.20. Removal of the Boc group was accomplished using 4M HCl and the 
resulting suspension was then condensed with cyanamide to give the trisubstituted 2-
aminoimidazole.  Hydrogenolysis of the benzyl group gave naamine A (1.16).  
Installation of the dehydrohydantoin was accomplished using Otha’s regioselective 
condensation procedure where 1-methyl-parabanic acid was first silylated with N,O-bis 
(trimethysilyl)acetamide (BSA), which was then reacted with 1.16 to give 1.2 in 80% 

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yield. Overall, Watson has improved the preparation of naamidine A from a fully 
protected tyrosine derivative in 8 linear steps and 20% overall yield.  
 
First generation synthesis by Looper research group 
While Ohta and Watson’s syntheses of naamidine A offer direct access to the 
natural product, the synthetic design does not allow for expansion of the 2-
aminoimidazole natural product catalogue.  Within the Looper research group, a one-pot 
addition-hydroamination-isomerization sequence was envisioned to rapidly access the 2-
aminoimidazole core of naamidine A not only to provide prompt access to naamidine A, 
but also to allow ease of functionalization for access to other category I/II alkaloid 
natural products and analogues (Figure 1.6).11  
This work has led to studies conducted by Dr. Robert Giles towards the synthesis 
of naamidine A (Figure 1.7).12  The propargyl cyanamides used in the study were 
constructed from a three-component iminium–acetylide addition (3-CC), which relied on 
stable precursors (an aldehyde, an amine, and an alkyne) to generate skeletal diversity. 
Beginning with alkyne 1.21, the 3-CC conditions were employed forming propargyl 
amine 1.22.  The intermediate was then subjected to Von Braun conditions to yield 
propargyl cyanamide 1.23.  The addition of an amine to 1.23 generated the propargyl 
guanidine followed by the addition of the N–H bond across the tethered alkyne. 
Isomerization of the resultant intermediate formed the imidazole core for 1.24.  This 
strategy allowed for substitution on every position of the 2-aminoimidazole in only three 
steps and thus streamlined the preparation of the 2-aminoimidazole core.  Following this 
was the deprotection of the piperidine ketal and hydrogenolysis to yield category I 

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natural product, naamine A (1.16).  Subjecting 1.16 to similar silylating conditions 
reported by Watson afforded naamidine A (1.2).  This convergent approach, completed in 
2008, had provided the highest yielding synthesis of naamidine A (6 steps, 41% overall 
yield).   
Interestingly, naamidine A and a number of category II alkaloids have been 
isolated as Zn2+ coordination complexes (Figure 1.8).6  The first of these complexes, 
described by Fattorusso, was a homodimer of clathridine A.  Further analysis of the X-ray 
crystal structure of 1.29 showed that the anionic clathridine acts as a bidentate ligand 
with dative bonding between both N-3 and N-8.6 
Although the specific role of the category II alkaloid zinc dimers in nature are not 
fully understood, interesting research published by Hergenrother and coworkers13 may 
offer clues to the unknown potential of these natural products.  Hergenrother investigated 
the nature of caspase-3, a cysteine-aspartic acid protease essential for cellular apoptosis, 
catalyzing the hydrolysis of a multitude of protein substrates within the cell (Figure 8).  
The levels of procaspase-3 are typically high in cancer cells, suggesting that compounds 
that directly stimulate the activation of procaspase-3 to caspase-3 could selectively 
induce apoptosis in cells.14  They reported that PAC-1 (1.29) and zinc form a tight 
complex with one another, suggesting that PAC-1 activates procaspase-3 in vitro by 
sequestering inhibitory zinc ions, thus allowing procaspase-3 to automatically activate 
itself to caspase-3 (Figure 1.9).  
With knowledge of category II alkaloid affinity for zinc and the phenotypic 
similarities between PAC-1 and naamidine A, we suspect that naamidine A and other 
category II alkaloid natural products may operate in a mechanism similar to that of PAC-

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1, for the initiation of cellular apoptosis by sequestering zinc.  Exploring this theory with 
the naamidines and their related zinc dimers affords a sensible preliminary investigation 
for the mechanistic rationale of the category II alkaloid natural products. 
 
Conclusion 
Nature has exploited the 2-aminoimidazole as a natural product scaffold.  Sponges 
of the genus Leucetta have provided an interesting class of highly substituted 2-
aminoimidazoles having been shown to probe a diverse range of biological processes.  
Naamidine A has gathered prominent synthetic interest since it’s preliminary biological 
evaluation.  It is expected that the 2-aminoimidazole will provide an excellent scaffold 
for the preparation of high value small molecules for discovery based research and high 












































Figure 1.2.  Selected examples of category I-IV 2-aminoimidazole natural products and 
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cell line               NIH3T3                HCT116
 
                       EGF    insulin        cytotoxicity
  1.2                 11.3       242                72
  1.5                 22.7       9.8               1154
  1.6                 36.9       6.7                288



















































1.12, X = Y = OH;
1.13, X = OH, Y = H or







1) TBSCl, Et3N, 
    DMAP, DMF (quant.)










1) Zn, HCl, AcOH, 80 oC
    (71% from 1.12)
    (70% from 1.13)
2) TBSCl, imidazole, DMF







1) NBS, THF 
    (72% yield)
2) t-BuLi; then TrsN3 
    (45% yield)
1) H2, Pd/C 
    (68% yield)
2) TBAF, THF 








































































1) 4M HCl in Et2O;
    then cyanamide, 
    H2O, pH 4.5, 90 oC
2) H2, Pd/C, MeOH










































Figure  1.7.  Looper first generation approach towards naamidine A. 
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1)  2M HCl, 
     MeCN, 95 oC, 12 h,
     then JandaJel-NH2,
     NH4Cl, EtOH
     95 oC, 12 h
2)  H2, Pd(OH)2,
     MeOH, rt, 2 h







































































































1.25, R1=R3=Me; R2=R4=H (naamidine A+A)
1.26, R1=R2=R3=R4=Me (naamidine G+G)













Figure 1.9.  (a) Chemical Structure of PAC-1.  (b) Procaspase 3 peptide domains D9, 
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SYNTHESIS OF NAAMIDINE A, RELATED NATURAL  
PRODUCTS AND ANALOGUES  
 
Introduction 
Based on the results from the preliminary investigation toward the synthesis of 
naamidine A and related natural products, modifications to the addition-hydroamination-
cyclization chemistry were proposed in order to address limitations for accessing the 2-
aminoimidazole core.  Under these conditions the stereo-electronically favored 5-exo-dig 
cyclization was observed followed by isomerization.  The major limitation of the 
methodology was that the addition of a nucleophile to the cyanamide was rate limiting 
and required forcing temperatures (>95 oC).  However, the expense of adding piperidine-
type nucleophiles and then removing their functionality to access the 2-aminoimidazole 
core resulted in variable reaction yields. 
The improved synthetic design towards naamidine A was initially envisioned to 
utilize milder reaction conditions allowing the use of a preformed propargyl guanidine to 
access both category I and II natural products.  Under the assumption that a π-Lewis acid 
might trigger the hydroamination process, a series of metal salts were evaluated by 
Looper and coworkers1 for their ability to affect the regioselective cyclization of an intact 

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N,N-diBoc-propargylguanidine. In the end, it was determined that Ag(I) catalysts were 
optimum for the formation of the formal 5-exo dig product. 
The improved synthetic approach (Figure 2.1) for access to the 2-aminoimidazole 
core now employed a secondary propargylamine (2.3) as the key intermediate still 
envisioned to come from established 3-CC procedures.  With the ability to control the 
regioselective cyclization of the propargylguanidine with silver salts, access to the 2-
aminoimidazole core can still be afforded by subsequent deprotection and condensation 
conditions to isolate the 2-aminoimidazole natural products, 2.1 and 2.2, respectively. 
 
Results and Discussion 
Synthesis of naamidine A 
The synthetic design for naamidine A began with the three-component coupling 
reaction (3-CC), which has been demonstrated for a number of substrates in high yields 
within the Looper research group2 and was met with similar success in the isolation of 
propargylamine 2.5, with all of the necessary functionality for what will become the 3-, 
4- and 5-positions of the imidazole core (Figure 2.2).  The propargyl amine was then 
subjected to mild acid-base reaction conditions for the generation of secondary amine 2.6.   
It was at this point where an efficient silver-catalyzed guanylation-cyclization 
reaction was employed.  It was proposed that the addition of a diBoc-
methylpseudothiourea to 2.6 in the presence of a weak base and metal catalyst would 
form a carbodiimide.  This intermediate would react in a tandem guanylation-cyclization 
step to yield either the 5-exo dig (2.7) or 6-endo dig cyclized products.  The addition of 
AgOAc with 2.6 afforded the 5-exo product in good selectivity and modest yield. The 

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regiomeric isomers could be successfully isolated, with the Boc-guanidine, 2.7, carried 
forward to the desired natural product. 
Naamidine A was ultimately obtained by the deprotection of the Boc groups and 
subsequent isomerization of 2.7 by treatment with acid to yield a category I type natural 
product, OBn-naamine A (2.8).  With this intermediate now accessible, the addition of 
the hydantoin tail was achieved by reaction conditions first reported by Watson3 for the 
synthesis of naamidine A.  The addition of naamine to a silyl-imidazolidinetrione, 
afforded the benzyl-protected naamidine A (2.9).  This was followed by the removal of 
the benzyl group functionality of 2.9 under standard hydrogenolysis conditions to yield 
naamidine A (2.10) in good yield (22% overall) and 6 total steps. 
 
Expansion of category II natural products 
It was thought that the layout for the synthesis of naamidine A could be applied to 
access several compounds containing the 2-aminoimidazole scaffold satisfying the 
characteristics of a category II natural product.  This was first implemented with the 
selection of the required amine, alkyne and aldehyde building blocks for the copper 
mediated 3-CC.  Several substrates were selected for the preparation of a series of 
propargylamines followed by the removal of the dimethoxybenzyl functionality upon 
treatment with TFAA, then NaOH for access to the secondary amine intermediates (2.3a-
e).  Not surprisingly, the robust reaction conditions offered a variety of intermediates in 
good yield.  Amines 2.3a and 2.3d were envisioned as a key intermediates for the 
synthesis of clathridine A and isonaamidine A, respectively.   
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The resultant propargyl amines were then subjected to the silver catalyzed tandem 
guanylation-cyclization with excellent regiomeric selectivity for the 5-exo dig cyclic Boc-
guanidine intermediates (2.11a-e, Figure 2.4).  The cyclized Boc-guanidines were then 
treated with TFA to yield the isomerized category I 2-aminoimidazole intermediates 
(2.2a-e, Figure 2.5).  It was initially proposed that this reaction could be coupled with the 
addition of TFA, where the deprotection of the Boc groups could be done in situ without 
the need for isolation and purification of 2.11a-e.  Unfortunately, the one-pot 
guanylation-cyclization-isomerization sequence was met with limited success, giving 
variable product yields across each secondary amine substrate.  Thus, at the risk of 
marginalizing the overall yield of the reaction sequence, the guanylation and subsequent 
Boc group deprotection-isomerization conditions were kept as independent reaction 
sequences. 
As anticipated, access to the category II natural products and analogues was 
achieved by the addition of 2.2a-e to silylated N-methylparabanic acid to yield the 
category II type natural products and analogues (2.1a-e, Figure 2.6).  The natural 
products, clathridine A (2.1a) and isonaamidine C (2.1d) were isolated as well as a series 
of three other analogues containing unique yet similar functional characteristics to other 
naamidine-like compounds as a method to probe any mechanistic overlap related to 
substitution around the heterocyclic core of the 2-aminoimidazole. 
 
Zinc binding and isothermal titration calorimetry studies 
With the initial isolation of clathridine A and its zinc homodimer, Fattorusso 
confirmed the presence of the zinc homodimer by the addition of ZnSO4 in CH2Cl2 to 
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isolated clathridine A.4  In an attempt to reproduce Fattorusso’s early findings of 
clathridine A as its zinc homodimer, our synthetic product, 2.1a, was treated with ZnSO4 
in solution of CH2Cl2 (Figure 2.7).  The obtained 1H NMR chemical shifts as well as 
mass spectral data proved to be consistent with Fattorusso’s initial characterization. 
As a measure for understanding the binding affinity of these category II natural 
product alkaloids, isothermal titration calorimetry was employed for a selection of 
prepared natural product alkaloids and analogues.  This approach allowed determination 
of the binding constants of our compounds by directly measuring the heat evolved in 
liquid samples as a result of mixing precise amounts of reactants.   
For this experiment, naamidine A as well as synthesized 2-aminoimidazole 
alkaloid natural products were prepared for calorimic titrations with the addition of a zinc 
(II) sulfate solution into a sample cell.  Control experiments with standard zinc binding 
ligand EDTA were applied before any of the synthesized products were used to ensure 
that proper mixing and changes due to dilution for each sample was accounted for in the 
determination of the binding constants.  The results of each calorimic titration are 
reported in Figure 2.9. 
The most interesting feature of the titration data is the significant change in 
binding affinity between the clathridine products.  The varied substitution of the aromatic 
ring in each of the products appears to play an important role in the strength of the N-3 
and N-8 positions.  The benzodioxole of clathridine A has created a stronger donating 
effect reducing the overall affinity of the molecule for zinc.  Comparison of these results 
with naamidine A also appears to support the idea that the presence of either electron 
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withdrawing or donating groups on the rings of the 2-aminoimidazole core plays an 
important role in binding.  
 
Conclusion 
In summary, the synthetic design for access towards naamidine A offers 
immediate access to the Leucetta natural product catalogue in 6 steps with improved 
yields for further study into its biological activity.  The binding studies of the naamidines 
and clathridines offer a point of reference for future experiements with the goal of 
confirming the mechanism of activity for naamidine A. 
 
Experimental Section 
General experimental procedures, materials and instrumentation 
Unless otherwise noted, materials were obtained from commercial sources and 
used without purification.  All reactions requiring anhydrous conditions were performed 
under a positive pressure of nitrogen using flame-dried glassware.  Triethylamine was 
distilled from CaH2 immediately prior to use.  Dichloromethane and toluene were 
degassed with argon and passed through a solvent purification system (J.C. Meyer of 
Glass Contour) containing either alumina or molecular sieves.   
Yields were calculated for material judged by thin-layer chromatography and 1H 
NMR.  Thin-layer chromatography was performed on Merck Kieselgel 60 F254 plates 
eluting with the solvents indicated, visualized by a 254 nm UV lamp, and stained with 
either an ethanolic solution of 12-molybdophosphoric acid, p-anisaldehyde, or KMnO4.  
Flash column chromatography was performed with Silicycle SiliaFlash® F60, slurry-

24
packed with solvents indicated in glass columns.  1H NMR spectra were recorded on 
Varian Unity-300, Inova-400, or VXR-500 MHz spectrometers as indicated.  The 
chemical shifts (δ) of proton resonances are reported relative to CDCl3, DMSO-d5, HOD, 
or HD2COD using the following format: chemical shift [multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, app = apparent), coupling constant(s) (J in 
Hz), integral].  1,2 13C NMR spectra were recorded at 75, 100, or 125 MHz.  The 
chemical shifts of carbon resonances are reported relative to the deuterated solvent peak26 
Infrared spectra were recorded on a Nicolet 380-FT IR spectrometer fitted with a 
SmartOrbit sample system.  All absorptions are reported in cm-1 relative to polystyrene.  
Mass spectra were obtained at the University of Utah CIF on a Micromass Quattro II 
(ESI/APCI) for LRMS or an LCT XE premier (ESI/APCI-TOF) for HRMS.  Isothermal 
titration calorimetry experiments were conducted using a MicroCal VP-ITC 
MicroCalorimeter fitted with Origin 7.0.  UV-Vis experiments were recorded using a 
Beckman DU 650 Spectrophotometer. 
 
 
1 - (4-(benzyloxy)phenyl) - N - (2,4 - dimethoxybenzyl) - 4 - (4 - methoxyphenyl) - N - 
methylbut-3-yn-2-amine 2.5.  Prepared from the CuBr catalyzed 3-CC of 2-(4-
(benzyloxy)phenyl)acetaldehyde, 1-(2,4-dimethoxyphenyl)-N-methylmethanamine, and 









Rf = 0.30 (50% EtOAc/hexanes); 1H NMR (CDCl3, 500 MHz): δ 7.44 (d, J = 7.3 Hz, 
2H), 7.41–7.35 (m, 5H), 7.32 (d, J = 6.8 Hz, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 
7.8 Hz, 1H), 6.91 (d, J = 8.3 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H), 6.45 (s, 1H), 6.42 (d, J = 
8.3 Hz, 1H), 5.06 (s, 2H), 3.82 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.74 (d, J = 13.2 Hz, 
1H), 3.52 (d, J = 13.2 Hz, 1H),  3.07–2.96 (m, 2H), 2.37 (s, 3H); 13C NMR (CDCl3, 125 
MHz): δ 160.1, 159.5, 159.1, 157.6, 137.5, 133.3, 131.8, 131.4, 130.7, 128.8, 128.1, 
127.7, 119.9, 116.0, 114.7, 114.0, 104.0, 98.8, 86.6, 85.9, 70.2, 59.1, 55.7, 55.6, 55.5, 
52.6, 39.9, 38.7; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.7, 55.6, 55.5, 38.7;  
CH2:, 70.2, 52.6, 39.9;  CH1: 133.3, 131.4, 130.7, 128.8, 128.1, 127.7, 114.7, 114.0, 
104.0, 98.8, 59.1;  CH0: 160.1, 159.5, 159.1, 157.6, 137.5, 131.8, 119.9, 116.0, 86.6, 
85.9;  IR (neat) 2928, 2836, 1607, 1587, 1508, 1454, 1418, 1380, 1289, 1245, 1208, 
1174, 1156, 1113, 1033, 919, 831, 737, 697 cm-1;  HRMS m/z (ESI) Calculated 
C34H36NO4 (M+H) 522.2647, Obsd. 522.2644. 
 
5-(4-(benzyloxy)benzyl)-4-(4-methoxybenzyl)-1-methyl-1H-imidazol-2-amine 2.8. 
Prepared to give 2.8 (88% yield) as a yellow oil. Rf = 0.30 (10% MeOH/CH2Cl2); 1H 
NMR (CDCl3, 500 MHz): δ 7.44–7.29 (m, 5H), 7.15 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 
Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 5.02 (s, 2H), 3.94 (bs, 2H), 
3.81 (s, 2H), 3.75 (s, 5H), 3.04 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 157.9, 157.6, 








55.4, 32.7, 29.4, 28.9; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.4, 29.4;  CH2: 
70.2, 32.7, 28.9;  CH1: 129.7, 129.1, 128.8, 128.2, 127.7, 121.2, 115.1, 113.9;  CH0: 
157.9, 157.6, 147.1, 137.2, 133.5, 133.3, 131.4, 121.2;  IR (neat) 3381, 3109, 2909, 1644, 
1611, 1552, 1510, 1248, 1174, 1030, 812, 737 cm-1;  HRMS m/z (ESI) Calculated 
C26H28N3O2 (M+H) 414.2182, Obsd. 414.2185. 
 
4-((5-(4-(benzyloxy)benzyl)-4-(4-methoxybenzyl)-1-methyl-1H-imidazol-2-yl)amino)-
1-methyl-1H-imidazole-2,5-dione 2.9.  Prepared to give 2.9 (60% yield) as a yellow oil.  
Rf = 0.32 (50% EtOAc/hexanes); IR (neat) 2924, 2852, 1716, 1653, 1635, 1602, 1559, 
1540, 1512, 1456, 1392, 1303, 1253, 1175, 1113, 1027, 834, 742 cm-1 
 
4-((5-(4-hydroxybenzyl)-4-(4-methoxybenzyl)-1-methyl-1H-imidazol-2-yl)amino)-1-
methyl-1H-imidazole-2,5-dione (Naamidine A) 2.10.  Prepared according to general 
procedure F, to give 2.10 (82% yield) as a bright yellow solid. Rf = 0.30 
(10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz): δ 7.12 (d, J = 8.5 Hz, 2H), 6.85 (d, 





















3H), 3.47 (s, 3H), 3.17 (s, 3H); IR (neat) 2923, 2853, 2179, 2038, 1787, 1744, 1590, 
1510, 1459, 1391, 1334, 1242, 1181, 1127, 1040, 1008 cm-1 
 
3-(benzo[d][1,3]dioxol-5-yl)-N-methylprop-2-yn-1-amine 2.3a.  To a 250 mL round-
bottomed flask containing a magnetic stir bar was added propargylamine (3.57 g, 10.53 
mmol, 1.0 equiv.), triethylamine (2.93 mL, 21.05 mmol, 2.0 equiv.), and CH2Cl2 (100 
mL).  The reaction mixture was allowed to stir at -78 oC for 5 min as trifluoroacetic 
anhydride (2.95 mL, 21.05 mmol, 2.0 equiv.) was added to the flask and allowed to stir 
for an additional 20 min.  100 mL of water was added to the reaction and allowed to stir 
for 10 min.  The organic portion of the reaction mixture was then isolated and solvent 
was removed under reduced pressure.  The product was then taken up in MeOH and 
added to a 250 mL round-bottomed flask containing a magnetic stir bar and 4 M NaOH 
(18 mL).  The reaction mixture was allowed to stir at rt for 4 h.  The reaction mixture was 
then concentrated under reduced pressure and taken up in CH2Cl2.  The organic portion 
was washed with a solution of saturated NaCl and concentrated under reduced pressure to 
give the secondary amine product 2.3a (1.67 g, 98% yield) as a clear oil.  Rf = 0.28 
(10% EtOAc/hexanes); 1H NMR (CDCl3, 500 MHz): δ 6.90 (dd, J = 1.5, 7.8 Hz, 1H), 
6.83 (d, J = 2.0 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 5.92 (s, 2H), 3.54 (s, 2H), 2.48 (s, 3H), 
1.17 (s, 1H); 13C NMR (CDCl3, 125 MHz): δ 147.9, 147.6, 126.3, 116.7, 112.0, 108.6, 







101.5, 41.1;  CH1: 126.3, 112.0, 108.6;  CH0: 147.9, 147.6, 116.7, 86.0, 83.5;  IR (neat) 
3335, 2892, 2789, 1603, 1502, 1485, 1438, 1327,1278, 1244, 1206, 1132, 1099, 1034, 
969, 932, 878, 859, 807, 722, 695, 615, 542 cm-1;  HRMS m/z (ESI) Calculated 
C11H12NO2 (M+H) 190.0876, Obsd. 190.0868. 
  
3-(4-(benzyloxy)phenyl)-N-methylprop-2-yn-1-amine 2.3b.  Prepared to give the 
secondary amine 2.3b (76 % yield) as a clear oil.  Rf = 0.36 (10% MeOH/CH2Cl2); 1H 
NMR (CDCl3, 500 MHz): δ 7.38–7.29 (m, 7H), 6.85 (d, J = 8.3 Hz, 2H), 5.02 (s, 2H), 
3.55, (s, 2H), 2.49 (s, 3H), 1.08 (s, 1H); 13C NMR (CDCl3, 125 MHz): δ 158.7, 136.7, 
133.2, 128.7, 128.2, 127.6, 115.8, 114.9, 86.3, 83.4, 70.1, 41.0, 35.6; 13C DEPT NMR 
(CDCl3, 125 MHz): δ CH3: 35.6;  CH2: 70.1, 41.0;  CH1: 133.2, 128.7, 128.2, 127.6, 
114.9;  CH0: 158.7, 136.7, 115.8, 86.3, 83.4;  IR (neat) 3035, 2931, 2791, 1605, 1568, 
1507, 1454, 1381, 1286, 1241, 1173, 1108, 1024, 831, 809, 737, 698, 599, 535 cm-1; 











N,4-dimethyl-1-phenylpent-1-yn-3-amine 2.3d.  Prepared to yield the secondary amine 
2.3d (90% yield) as an orange oil. Rf = 0.29 (20% EtOAc/hexanes); 1H NMR (CDCl3, 
500 MHz): δ 7.40-7.35 (m, 2H), 7.33-7.27 (m, 2H), 6.86 (dddd, J = 18.0, 8.0, 5.0, 5.0 
Hz, 4H), 3.88 (s, 2H), 3.81 (s, 3H), 3.80 (s, 3H) 3.62 (s, 2H); 13C NMR (CDCl3, 500 
MHz): δ 133.2, 132.3, 132.2, 132.1, 132.0, 129.8, 128.7, 128.6, 114.1, 114.0, 113.9, 55.4, 
52.0, 38.2; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.4; CH2: 52.0, 38.2; CH1: 
133.2, 132.1, 129.8, 128.7, 114.1; CH0: 132.3, 132.1, 132.0, 128.6, 114.0, 113.9;  
IR (neat) 2932, 2835, 1606, 1510, 1463, 1439, 1291, 1248, 1174, 1119, 1032, 833, 750, 
721, 696, 541 cm-1;  HRMS m/z (ESI) Calculated C18H20NO2 (M+H) 282.1497, 
Obsd. 282.1494. 
 
N,A-dimethyl-1-phenylpent-1-yn-3-amine 2.3e.  Prepared to give secondary 
propargylamine 2.3e (91% yield) as a yellow oil.  Rf = 0.45 (10% MeOH/CH2Cl2); 1H 
NMR (CDCl3, 500 MHz): δ 7.45–7.41 (m, 2H), 7.33–7.30 (m, 3H), 3.25 (d, J = 5.7 Hz, 
2H), 2.57 (s, 3H), 1.95, (app d7, J = 6.6, 10.3 Hz, 1H), 1.78 (s, 1H), 1.07 (t, J = 4.4 Hz, 
6H); 13C NMR (CDCl3, 125 MHz): δ 131.8, 128.7, 128.0, 114.1, 89.4, 84.8, 59.1, 55.4, 
34.7, 32.8, 19.9, 18.0; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 34.7, 19.9, 18.0; CH1: 
131.8, 128.7 128.3, 128.0, 114.1, 59.1, 32.8;  CH0: 89.4, 84.8, 55.4;  IR (neat) 2959, 
2870, 2794, 2361, 2339, 1598, 1512, 1489, 1467, 1442, 1384, 1366, 1343, 1323, 1300, 
1246, 1171, 1131, 1105, 1070, 1029, 914, 817, 755, 691, 668 cm-1;  HRMS m/z (ESI) 









(5Z) - tert - butyl - 5 - (benzo[d][1,3]dioxol - 5 - ylmethylene) - 2-((tert -
butoxycarbonyl)imino)-3-methylimidazolidine-1-carboxylate 2.11a.  To a 25 mL 
round-bottomed flask containing a magnetic stir bar was added secondary 
propargylamine (0.437 g, 2.31 mmol, 1.0 equiv.), 1,3-Bis(tert-butoxycarbonyl)-2-methyl-
2-pseudothiourea (0.677 g, 2.31 mmol, 1.0 equiv.), AgOAc (0.578 g, 3.47 mmol, 1.5 
equiv.), triethylamine (1.7 mL, 11.55 mmol, 5.0 equiv.), and CH2Cl2 (24 mL).  The 
reaction mixture was allowed to stir under N2 at rt for 24 h. The reaction mixture was 
filtered through a plug of celite before the solvent was removed under reduced pressure.  
Purification of the material was accomplished by flash column chromatography on a 5.7 
× 15 cm column, eluting with 200 mL 50% EtOAc/hexanes, 200 mL 70% 
EtOAc/hexanes, then 90% EtOAc/hexanes.  The product containing fractions were 
combined and then concentrated under reduced pressure to give the 5-exo-dig imidazole 
2.11a (0.699 g, 70% yield) as a light brown oil.  Rf = 0.33 (90% EtOAc/hexanes); 1H 
NMR (CDCl3, 500 MHz): δ 6.94 (d, J = 2.0 Hz, 1H), 6.80 (dd, J = 1.5, 8.3 Hz, 1H), 6.72 
(d, J = 7.8 Hz, 1H), 5.90 (s, 2H), 5.85 (s, 1H), 3.96 (d, J = 1.5 Hz, 2H), 2.96 (s, 2H), 1.52 
(s, 9H), 1.08 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ 159.4, 152.0, 148.6, 147.7, 146.9, 
130.1, 127.9, 123.0, 116.0, 109.1, 108.2, 101.2, 83.6, 79.5, 52.8, 31.8, 27.5, 27.7; 13C 
DEPT NMR (CDCl3, 125 MHz): δ CH3: 31.8, 27.5, 27.7;  CH2: 101.2, 52.8;  CH1: 123.0, 
116.0, 109.1, 108.2;  CH0: 159.4, 152.0, 148.6, 147.7, 146.9, 130.1, 127.9, 83.6, 79.5 ;  









1254, 1236, 1150, 1060, 1037, 956, 929, 872, 846, 795, 768, 733, 667 cm-1;  HRMS m/z 
(ESI) Calculated C22H30N3O6 (M+H) 432.2146, Obsd. 432.2135. 
 
(5Z)-tert-butyl-5-(4-(benzyloxy)benzylidene)-2-((tert-butoxycarbonyl)imino)-3-
methylimidazolidine-1-carboxylate 2.11b.  Prepared to give 2.11b (75% yield) as a 
light brown oil.  Rf = 0.29 (50% EtOAc/hexanes1H NMR (CDCl3, 500 MHz):  δ 7.41 (d, 
J = 6.8 Hz, 2H), 7.36 (t, J = 7.3 Hz, 3H), 7.33–7.31 (m, 2H), 6.92 (d, J = 8.8 Hz, 2H), 
5.92 (s, 1H), 5.09 (s, 2H), 4.00 (d, J = 2.0 Hz, 2H), 3.00 (s, 3H), 1.56 (s, 9H), 1.02 (s, 
9H); 13C NMR (CDCl3, 125 MHz): δ 159.5, 157.8, 152.1, 148.5, 137.0, 130.1, 128.9, 
128.7, 128.0, 127.5, 115.7, 114.7, 83.4, 79.1, 70.0, 52.7, 31.7, 28.3, 27.4; 13C DEPT 
NMR (CDCl3, 125 MHz): δ CH3: 31.7, 28.3, 27.4;  CH2: 70.0, 52.7;  CH1: 130.1, 128.7, 
128.0, 127.5, 115.7, 114.7, 77.5;  CH0: 159.5, 157.8, 152.1, 148.5, 137.0, 128.9, 127.5, 
83.4, 79.1;  IR (neat) 2977, 2927, 1745, 1711, 1688, 1679, 1631, 1607, 1511, 1468, 1453, 
1367, 1299, 1245, 1175, 1148, 1024, 847, 743, 697 cm-1;  HRMS m/z (ESI) Calculated 














(5Z) - tert – butyl - 5 – benzylidene - 2 - ((tert - butoxycarbonyl)imino) - 4 - isopropyl 
- 3-methylimidazolidine-1-carboxylate 2.11d.  Prepared to give 2.11d (72% yield) as a 
light yellow oil.  Rf = 0.30 (50% EtOAc/hexanes); 1H NMR (CDCl3, 500 MHz):  δ 7.32 
(d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.3 Hz, 2H), 6.84 (d, J = 8.3 Hz, 
2H),  5.84 (s, 1H), 4.57 (s, 2H), 3.81 (s, 3H), 3.80 (s, 2H), 3.79 (s, 3H), 1.59 (s, 9H), 1.05 
(s, 9H); 13C NMR (CDCl3, 125 MHz): δ 159.7, 159.5, 159.4, 152.1, 148.6, 130.1, 130.0, 
128.7, 127.5, 127.4, 115.9, 114.2, 113.6, 83.5, 79.3, 55.4, 55.3, 49.6, 47.9, 28.3, 27.5; 13C 
DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.4, 55.3, 28.3, 27.5;  CH2: 49.6, 47.9;  CH1: 
130.1, 130.0, 115.9, 114.2, 113.6;  CH0: 159.7, 159.5, 159.4, 152.1, 148.6, 128.7, 127.5, 
127.4, 83.5, 79.3;  IR (neat) 2918, 2849, 2362, 2339, 2228, 2168, 2158, 2141, 2118, 
1745, 1684, 1634, 1610, 1513, 1457, 1393, 1367, 1301, 1249, 1175, 1151, 1123, 1033, 
851, 767, 668, 568, 540 cm-1;  HRMS m/z (ESI) Calculated C29H38N3O6 (M+H) 
524.2769, Obsd. 524.2761.  
 
(5Z) - tert - butyl - 5 - benzylidene - 2 - ((tert - butoxycarbonyl)imino) - 4 - 
isopropyl-3-methylimidazolidine-1-carboxylate 2.11e.  Prepared to give 2.11e 
(71% yield) as a light yellow oil.  Rf = 0.29 (50% EtOAc/hexanes); 1H NMR (CDCl3, 500 
MHz):  δ 7.43 (s, J = 7.8 Hz, 2H), 7.31 (t, J = 7.8 Hz, 2H), 7.26–7.15 (m, 5H), 6.99 (d, J 
= 8.8 Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 5.88 (s, 1H), 4.68 (dd, J = 12.2, 257.3 Hz, 1H), 
3.78 (s, 1H) 3.75 (d, J = 3.4 Hz, 1H); 13C NMR (CDCl3, 125 MHz): δ 159.8, 159.6, 









117.8, 113.7, 112.8, 83.1, 79.2, 68.5, 66.4, 55.3, 31.3, 31.0, 30.8, 29.2, 28.4, 27.3, 18.2, 
17.6, 16.0, 15.8; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.3, 31.3, 30.8, 29.2, 28.4, 
27.3, 18.2, 17.6, 16.0, 15.8; CH1: 130.2, 128.8, 128.4, 128.2, 127.6, 127.2, 127.0, 117.8, 
113.7, 112.8, 68.5, 66.4, 31.0;  CH0: 159.8, 159.6, 152.6, 148.0, 136.1, 136.0, 131.9, 
130.8, 83.1, 79.2;  IR (neat) 2964, 2931, 1782, 1746, 1710, 1681, 1634, 1515, 1449, 
1388, 1366, 1296, 1234, 1169, 1146, 1060, 973, 921, 852, 800, 771, 730, 697, 668, 602 
cm-1;  HRMS m/z (ESI) Calculated C24H36N3O4 (M+H) 430.2708, Obsd. 430.2706. 
 
 (4-(benzo[d][1,3]dioxol-5-ylmethyl)-1-methyl-1H-imidazol-2-amine) 2.2a.  To a 50 
mL round-bottomed flask containing a magnetic stirbar was added imidazole 2.11a (0.15 
g, 0.36 mmol, 1.0 equiv.), trifluoroacetic acid (1.4 mL, 18.03 mmol, 50 equiv.), and 
CH2Cl2 (4 mL).  The reaction mixture was allowed to stir at reflux for 1.5 h.  The 
solution was washed with 2M NaOH (20 mL) and the organic layer was dried over 
NaSO4 and concentrated under reduced pressure to give 2.2a,  (0.081 g, 91% yield) as a 
yellow oil.  Rf = 0.33 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz):  δ 6.71 (s, 
1H), 6.67 (d, J = 1.0 Hz, 2H), 6.08 (s, 1H), 5.86 (s, 2H), 3.62 (s, 2H), 3.29 (s, 3H); 13C 
NMR (CDCl3, 125 MHz): δ 147.7, 146.0, 137.3, 134.4, 121.8, 113.2, 109.6, 108.3, 101.0, 
34.8, 31.5; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 31.5;  CH2:  101.0, 34.8;  CH1:  
121.8, 113.2, 109.6, 108.3;  CH0:  147.7, 146.0, 137.3, 134.4;  IR (neat) 3117, 2900, 









775, 713, 660 cm-1;  HRMS m/z (ESI) Calculated C12H14N3O2 (M+H) 232.1094, 
Obsd. 232.1086. 
 
4-(4-(benzyloxy)benzyl)-1-methyl-1H-imidazol-2-amine 2.2b.  Prepared to give 2.2b, 
(70% yield) as a light yellow oil.  Rf = 0.45 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 
MHz): δ 7.38–7.25 (m, 5H), 7.12 (d, J = 8.3 Hz), 6.85 (d, J = 8.3 Hz), 5.95 (s, 1H), 4.98 
(s, 2H), 3.64 (s, 2H), 3.24 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 157.4, 147.8, 137.3, 
135.6, 132.2, 129.9, 128.7, 128.0, 127.6, 114.9, 112.8, 70.1, 33.4, 31.5; 13C DEPT NMR 
(CDCl3, 125 MHz): δ CH3: 70.1, 31.5; CH2: 33.4;  CH1: 129.9, 128.7, 128.0, 127.6, 
114.9, 112.8;  CH0: 157.4, 147.8, 137.3, 135.6, 132.2;  IR (neat) 3033, 2927, 2869, 1722, 
1642, 1601, 1508, 1454, 1405, 1381, 1342, 1289, 1245, 1172, 1135, 1077, 1024, 913, 
832, 793, 739, 697, 617 cm-1; HRMS m/z (ESI) Calculated C18H20N3O (M+H) 294.1607 
Obsd. 294.1606. 
 
1-methyl-4-(4-(trifluoromethyl)benzyl)-1H-imidazol-2-amine 2.2c.  Prepared to give 
2.2c (97% yield) as a yellow oil.  Rf = 0.27 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 
MHz):  δ 7.59 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.3 Hz, 2H), 6.02 (s, 1H), 3.87 (s, 2H), 













31.8, 31.2; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 31.8;  CH2: 31.2;  CH1: 129.3, 
126.0, 112.6;  CH0: 147.9, 132.4, 38.7;  IR (neat) 3140, 2924, 2177, 1674, 1547, 1422, 
1326, 1203, 1174, 1126, 1067, 1019, 837, 799, 722, 597 cm-1;  HRMS m/z (ESI) 
Calculated C12H13F3N3 (M+H) 256.1062, Obsd. 256.1062. 
 
4-benzyl-5-isopropyl-1-methyl-1H-imidazol-2-amine 2.2d.  Prepared to give 2.2d 
(35% yield) as a light yellow oil.  Rf = 0.20 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 
MHz): δ  7.19 (d, J = 8.5 Hz, 2H), 7.06 (d, J = 8.5, 2H), 6.86 (d, J = 8.5, 2H), 6.82 (d, J 
= 8.5 Hz, 2H), 6.14 (s, 1H), 4.74 (s, 2H), 3.93 (s, 2H), 3.79 (s, 3H), 3.78 (s, 3H); 13C 
NMR (CDCl3, 125 MHz): δ 159.7, 158.2, 147.6, 137.6, 132.5, 130.1, 128.6, 128.3, 114.7, 
114.1, 112.8, 55.7, 55.6, 48.5, 34.3 ; IR (neat) 3345, 2934, 2838, 1739, 1666, 1610, 1513, 
1453, 1392, 1302, 1249, 1177, 1031, 835, 756, 610, 562 cm-1;  HRMS m/z (ESI) 
Calculated C19H22N3O2 (M+H) 324.1702, Obsd. 324.1712. 
 
4-benzyl-5-isopropyl-1-methyl-1H-imidazol-2-amine 2.2e.  Prepared to give 2.2e 
(88% yield) as a light yellow oil.  Rf = 0.10 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 














(s, 3H); 13C NMR (CDCl3, 125 MHz): δ 147.0, 137.7, 128.9, 128.3, 127.5, 126.9, 120.5, 
30.6, 29.8, 24.5, 21.3; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 29.8, 21.3;  CH2: 
30.6;  CH1: 24.5;  CH0: 147.0, 137.7, 127.5, 120.5;  IR (neat) 3136, 2968, 2925, 2361, 
2338, 1734, 1669, 1635, 1558ha 
 
Clathridine A (4-((4-(benzo[d][1,3]dioxol-5-ylmethyl)-1-methyl-1H-imidazol-2-
yl)amino)-1-methyl-1H-imidazole-2,5-dione) 2.1a.  1-methylparabanic acid (0.361 g, 
2.80 mmol, 8 equiv.) in MeCN (2.5 mL) was treated with N,O-
bis(trimethylsilyl)acetamide (857 μL, 3.50 mmol, 10 equiv.) and stirred at reflux for 1 h. 
The yellow solution was concentrated to dryness under vacuum, opened to dry N2 to 
minimize exposure to air of the silylated product. The residue was taken in toluene (3.5 
mL) and added to 2.2a (0.081 g, 0.35 mmol, 1.0 equiv).  The mixture was stirred 
overnight at reflux then diluted with EtOAc (25 mL) and washed with H2O.  The organic 
layer was dried over Na2SO4 and concentrated to dryness. Purification of the material was 
accomplished by flash column chromatography on a 5.7 × 15 cm column, eluting with 
100 mL CH2Cl2, 200 mL 1% MeOH/CH2Cl2, 200 mL 5% MeOH/CH2Cl2 then 10% 
MeOH/CH2Cl2.  The product containing fractions were combined and then concentrated 
under reduced pressure to give clathridine A, 2.1a, (0.080 mg, 66% yield) as a yellow oil.  
Rf = 0.55 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz): δ 6.69 (d, J = 7.3 Hz, 1H), 














3H), 3.11 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 162.0, 155.0, 147.9, 147.1, 146.3, 
144.2, 139.8, 132.8, 121.7, 117.7, 109.3, 108.4, 101.0, 34.5, 32.2, 24.8; 13C DEPT NMR 
(CDCl3, 125 MHz): δ CH3: 32.2, 24.8;  CH2:  101.0, 34.5;  CH1: 121.7, 117.7, 109.3, 
108.4;  CH0:  162.0, 155.0, 147.9, 147.1, 146.3, 144.2, 139.8, 132.8 ;  IR (neat) 2922, 
1792, 1736, 1667, 1620, 1565, 1501, 1488, 1443, 1391, 1308, 1246, 1213, 1115, 1037, 
927, 809, 725, 701, 597 cm-1;  HRMS m/z (ESI) Calculated C16H16N5O4 (M+H) 
342.1219, Obsd. 342.1202. 
 
4 - ((4 - (4 - (benzyloxy)benzyl) - 1 - methyl - 1H - imidazol - 2 - yl)amino) - 1-methyl-
1H-imidazole-2,5-dione 2.1b.  Prepared to give 2.1b (83% yield) as a red crystalline 
solid.  mp = 189-190 OC;  Rf = 0.61 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz): 
δ 7.40–7.28 (m 5H), 7.12 (d, J = 8.3 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 6.43 (s, 1H), 5.00 
(s, 2H), 3.79 (s, 2H), 3.69 (s, 3H), 3.13 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 162.3, 
157.7, 155.6, 147.1, 139.5, 137.2, 131.2, 129.9, 129.6, 128.7, 128.1, 127.6, 117.6, 115.1, 
70.2, 33.8, 32.2, 24.8; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 32.2, 24.8; CH2: 70.2, 
33.8; CH1: 129.9, 128.7, 128.1, 127.6, 117.6, 115.1;  CH0: 162.3, 157.7, 155.6, 147.1, 
139.5, 137.2, 131.2, 129.6; IR (neat) 3258, 3032, 2945, 1792, 1735, 1668, 1610, 1564, 
1509, 1444, 1390, 1304, 1242, 1175, 1144, 1115, 1040, 1025, 910, 842, 776, 727, 698, 















imidazole-2,5-dione 2.1c.  Prepared to give 2.1c (65% yield) as a yellow oil.  Rf = 0.62 
(10% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz): δ 7.55 (d, J = 8.3 Hz, 2H), 7.36 (d, J 
= 8.3 Hz, 2H), 6.57 (s, 1H), 3.95 (s, 2H), 3.72 (s, 3H), 3.18 (s, 3H); 13C NMR (CDCl3, 
125 MHz): δ 161.7, 154.1, 147.2, 143.5, 142.7, 139.3, 129.2, 125.7, 118.1, 113.3, 34.8, 
32.2, 24.8; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 32.2, 24.8;  CH2: 34.8;  CH1: 
129.2, 125.7, 118.1;  CH0: 161.7, 154.1, 147.2, 143.5, 142.7, 139.3, 113.3, 31.4;  
IR (neat) 2931, 2584, 2186, 1794, 1742, 1672, 1617, 1558, 1448, 1393, 1325, 1163, 
1121, 1067, 1019, 726, 611 cm-1;  HRMS m/z (ESI) Calculated C16H14F3N5O2Na (M+Na) 
388.1010, Obsd. 388.0997. 
 
4-((4-benzyl-5-isopropyl-1-methyl-1H-imidazol-2-yl)amino)-1-methyl-1H-imidazole-
2,5-dione 2.1d.  Prepared to give 2.1d (90% yield) as yellow solid. Rf = 0.20 (70% 





















6.84 (dddd, J = 9.0, 3.0, 3.0, 3.0 Hz, 4H), 6.45 (s, 1H), 5.19 (s, 2H), 3.81 (s, 2H), 3.79 (s, 
3H), 3.78 (s, 3H), 3.19 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 162.5 159.7, 158.4, 
156.1, 146.9, 146.1, 139.6, 130.8, 129.9, 129.6, 128.4, 116.1, 114.4, 114.2, 55.5, 55.5, 
48.6,  33.9, 25.0; IR (neat) 3249, 1789, 1737, 1666, 1611, 1512, 1449, 1392, 1335, 1246, 
1116, 1041, 756, 650, 553 cm-1 
 
4-((4-benzyl-5-isopropyl-1-methyl-1H-imidazol-2-yl)amino)-1-methyl-1H-imidazole-
2,5-dione 2.1e.  Prepared to give 2.1e (70% yield) as a yellow oil.  Rf = 0.40 
(50% EtOAc/hexanes); 1H NMR (CDCl3, 500 MHz): δ 7.12 (d, J = 1.3 Hz, 2H), 7.05–
6.99 (m, 3H), 3.85 (s, 2H), 3.58 (s, 3H), 2.99 (s, 3H), 2.94 (m, 1H), 1.13 (s, 3H), 1.11 (s, 
3H); 13C NMR (CDCl3, 125 MHz): δ 157.3, 153.0, 146.3, 133.3, 128.8, 128.4, 126.6, 
33.2, 30.6, 25.1, 25.0, 24.9, 21.5; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 30.6, 25.0, 
24.9, 21.5;  CH2: 33.2;  CH1: 128.8, 128.4, 126.6, 25.1;  CH0: 157.3, 153.0, 146.3, 133.3;  
IR (neat) 3340, 2924, 2854, 1784, 1727, 1678, 1460, 1395m 1345, 1149, 1040, 770, 721, 










































































-78 oC to rt, 15 min
 then NaOH(aq)/MeOH, 





AgOAc (1.5 equiv) 
Et3N, CH2Cl2, rt, 24 h





































10 mol % Pd/C, H2
EtOAc, rt, 24 h
82% yield
2.4 2.5
2.6 2.7, 5-exo:6-endo = 10:1
2.8










1) 10 mol% CuBr, MeCN
2) TFAA, Et3N 
    -78 oC to rt, 15 min,
    then NaOH(aq)/MeOH, 




























































Figure 2.4.  Synthesis of 5-exo cyclized Boc protected guanidines. 


























































































































































































































































































































Entry Compound Kd  (μM) 
1 Naamidine A (2.10) 31.3 
2 Clathridine A (2.1a) 8.3 
3 Clathridine C >500 
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EXPANSION OF 2-AMINOIMIDAZOLE CHEMISTRY: SYNTHESIS OF  
2-THIO AND 2-OXOIMIDAZOLES 
 
Introduction 
 2-thio and 2-oxoimidazoles represent a medicinally important heterocyclic 
scaffold.  These target substructures are central to compounds possessing inhibitory 
activity against HIV-1 reverse transcriptase1 and p38 MAP kinase2 as well as histamine-
H3 antagonists (Figure 3.1).3  They have also been documented as key pharmacophores in 
agents for the treatment of thrombosis,4 inflammation and asthma.5 The reaction 
sequence developed for access to 2-aminoimidazoles via a one-pot addition-
hydroamination-isomerization sequence developed by Giles and coworkers6 (Figure 3.2) 
was soon adapted to the addition of thiol, phenol and alcohol nucleophiles for the 
formation of 2-thio and 2-oxoimidazoles.7 
 
Results and Discussion 
One of the key aspects to this chemistry is the rapid preparation of the 
propargylcyanamide precursors (Figure 3.3).  The propargylcyanamides (3.2a-d) used in 
this study were prepared in two steps by an iminium-acetylide three-component coupling 

50
(3-CC) to give the propargylamines 3.1a-d.8 Cleavage of the tertiary amine with 
cyanogen bromide via von Braun reaction conditions gave the propargylcyanamides 
3.2a-d with cleavage of the intermediate cyanoammonium salt at the activated benzylic 
position of the PMB group.9 
The addition of neutral thiols to initiate the addition-cyclization-isomerization 
sequence was initially investigated.  After heating a solution of the propargylcyanamide 
3.2a with ethanethiol for 24 h, the formation of the desired product was observed, 
although approximately 5% of the propargylcyanamide had been converted.  The poor 
electrophilic nature of N,N-dialkylcyanamides suggested that a Lewis acid catalyst or an 
anionic species would be required to affect addition to the cyanamide.10,11 In contrast to 
the addition of amines to propargylcyanamides, lanthinum did not catalyze product 
formation.6  Fortunately, the addition of 5 equiv of Hunig’s base in the reaction mixture 
improved the nucleophilicity led to complete consumption of the propargylcyanamide 
after only 12 h at 120 oC to give 2-ethylthioimidazole 3.3a in a 67% yield (Figure 3.4, 
entry 1). Treatment of the other cyanamides under the same conditions gave comparable 
results (entries 2-4).  Benzylic thiols also gave the 2–thioimidazoles in moderate to good 
yields (Figure 3.4, entries 5-8). 
Thiophenols are also competent partners in this reaction sequence (Figure 3.4, 
entries 9-12) and react chemoselectively in the presence of phenols (Figure 3.4, entries 
13-16).  For experimental convenience, an excess of thiol in the addition-cyclization-
isomerization sequence was used; however, the use of dithiols in the presence of 1.5 
equivalents of cyanamide per thiol was capable of producing bis-2-thioimidazoles 3.7a 
and 3.7b in good yields (Figure 3.5).  Since it was noted that isopropanol was a 

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noncompetitive solvent for the lanthinum catalyzed addition of amines to cyanamides, it 
was not surprising to observe that they were not competent nucleophiles in the addition-
cycloisomerization sequence under neutral conditions.6  
The developed chemistry requires a fine balance of nucleophilicity and basicity to 
affect addition to the cyanamide without formation of the allenyl-cyanamide, which 
readily decomposes.  The inclusion of an oxygen substituent bearing an adjacent sp2 
hybridized carbon atom allowed for broadened substituent diversity.  It was previously 
observed that sterically hindered alkoxides (KOtBu in THF) quantitatively isomerized 
propargylcyanamides to the allenyl-cyanamide in ∼10 min at 0 oC.  Due to the increased 
basicity of alkoxides relative to thiolates, which could favor isomerization over addition 
to the cyanamide, it was expected that phenoxides or alkoxides would not be competent 
nucleophiles in this chemistry.  Contrary to this assumption, treatment of cyanamide 3.2a 
with phenol in the presence of K2CO3 successfully delivered the 2-phenoxyimidazole 
(3.8a) in 77% yield (Figure 3.6).  Toluene proved to be the best solvent for temperature 
considerations. 
The nucleophile selection was then expanded to alkoxides quickly revealing that 
treatment of 3.2c with MeOH and Hunig’s base gave the methoxyimidazole 3.9a in 72% 
yield (Figure 3.7, entry 1). Interestingly, iPrOH, the solvent choice for the La(III) 
catalyzed amine addition–hydroamination–isomerization manifold, afforded the 2–






In conclusion, optimal conditions have been developed for the addition of both 
alkyl and aryl thiols and alcohols to propargylcyanamides.  Subsequent 
cycloisomerization delivers the 2-thio- or 2-oxoimidazoles in good yields.  The fact that 
equimolar KOtBu decomposes the substrates but catalytically generated nucleophiles 
(e.g., K2CO3/iPrOH) are competent partners suggests that thio- or oxo-nucleophiles with 
a pKa < ∼18 should be tolerated under these conditions.  Interestingly, La(III) does not 
influence the reaction of thio- or oxo-nucleophiles with propargylcyanamides, suggesting 




General experimental procedures, materials and instrumentation 
Unless otherwise noted, materials were obtained from commercial sources and 
used without purification.  All reactions requiring anhydrous conditions were performed 
under a positive pressure of nitrogen using flame-dried glassware.  Triethylamine was 
distilled from CaH2 immediately prior to use.  Dichloromethane and toluene were 
degassed with argon and passed through a solvent purification system (J.C. Meyer of 
Glass Contour) containing either alumina or molecular sieves.   
Yields were calculated for material judged homogeneous by thin-layer 
chromatography and 1H NMR.  Thin-layer chromatography was performed on Merck 
Kieselgel 60 F254 plates eluting with the solvents indicated, visualized by a 254 nm UV 

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lamp, and stained with either an ethanolic solution of 12-molybdophosphoric acid, p-
anisaldehyde, or KMnO4.  Flash column chromatography was performed with Silicycle 
SiliaFlash® F60, slurry-packed with solvents indicated in glass columns.  1H NMR 
spectra were recorded on Varian Unity-300, Inova-400, or VXR-500 MHz spectrometers 
as indicated.  The chemical shifts (δ) of proton resonances are reported relative to CDCl3, 
DMSO-d5, HOD, or HD2COD using the following format: chemical shift [multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet, app = apparent), coupling 
constant(s) (J in Hz), integral].  1,2 13C NMR spectra were recorded at 75, 100, or 125 
MHz.  The chemical shifts of carbon resonances are reported relative to the deuterated 
solvent peak Infrared spectra were recorded on a Nicolet 380-FT IR spectrometer fitted 
with a SmartOrbit sample system.  All absorptions are reported in cm-1 relative to 
polystyrene.  Mass spectra were obtained at the University of Utah CIF on a Micromass 
Quattro II (ESI/APCI) for LRMS or an LCT XE premier (ESI/APCI-TOF) for HRMS.  
 
 
N,N-bis(4-methoxybenzyl)-3-(4-methoxyphenyl)prop-2-yn-1-amine 3.1a. To a 100 
mL round-bottomed flask containing a magnetic stir bar was added bis(4-
methoxybenzyl)amine (PMB2NH) (3.73 g, 14.5 mmol, 1.0 equiv.), 37% aqueous solution 
of formaldehyde (6.54 g, 6.00 mL, 80.6 mmol, 5.6 equiv.), 4-methoxyphenyl acetylene 
(2.02 g, 15.3 mmol, 1.06 equiv.), CuBr (0.209 g, 1.45 mmol, 0.1 equiv.) and MeCN (45 
mL). The reaction mixture was allowed to stir at rt for 24 h. The reaction mixture was 






Purification of the material was accomplished by flash column chromatography on a 5.7 
× 15 cm column, eluting with 20% EtOAc/hexanes.  The product containing fractions 
were combined and then concentrated under reduced pressure to give propargylamine 
3.1a (5.77 g, 98% yield) as a light yellow oil.  Rf  = 0.49 (35% EtOAc/hexanes); 1H NMR 
(CDCl3, 500 MHz): δ 7.45 (d, J = 14 Hz, 2H), 7.35 (d, J = 8.0 Hz, 4H), 6.90-6.86 (m, 
6H), 3.83 (s, 3H), 3.80 (s, 6H), 3.67 (s, 4H), 3.43 (s, 2H); 13C NMR (CDCl3, 125 MHz): δ 
159.6, 159.0, 133.4, 131.3, 130.5, 115.8, 114.2, 113.9, 85.8, 83.2, 57.1, 55.6, 55.5, 42.0;  
13C DEPT NMR (CDCl3, 125 MHz): δ CH3: (2 × 55.4); CH2: 57.0, 41.8; CH1: 133.3, 
132.3, 131.1, 114.0, 113.8; CH0: 158.9, 85.8, 83.2;  IR (neat): 2933, 2834, 1607, 1509, 
1463, 1291, 1246, 1172, 1106, 1034, 832, 668 cm-1. HRMS (ESI) Calculated for 
C26H28NO3 m/z (M+H) 402.2069, Obsd. 402.2055. 
 
N-benzyl-N-(4-methoxybenzyl)-3-phenylprop-2-yn-1-amine 3.1b.  Obtained from the 
CuBr catalyzed 3-CC of formaldehyde, (PMB(Bn)NH), and phenylacetylene to give 
propargylamine 3.1b as a clear as a clear oil in 90% yield.  Rf = 0.25 (20% 
EtOAc/hexanes); 1H NMR (CDCl3, 500 MHz): δ 7.51-7.50 (m, 2H), 7.42 (d, J = 7.3 Hz, 
1H), 7.35-7.31 (m, 6H), 7.23-7.25 (m, 4H), 6.88 (d, J = 8.3 Hz, 2H), 3.81 (s, 3H), 3.74 (s, 
2H), 3.69 (s, 2H), 3.69 (s, 2H); 13C NMR (CDCl3, 125 MHz): δ 159.9, 139.2,132.0, 
131.1, 130.4, 129.3, (2 × 128.5), 128.2, 127.3, 123.7, 113.9, 86.1, 84.7, 57.8, 57.3, 55.5, 
42.0;  DEPT 13C NMR (CDCl3, 125 MHz): δ CH3: 55.5; CH2: 57.8, 57.3, 42.0; CH1: 
132.0, 130.4, 129.3, (2 × 128.5), 128.2, 127.3, 113.9; CH0: 159.9, 139.2, 131.1, 123.7, 






1425, 1362, 1322, 1300, 1244, 1170, 1101, 1071, 1034, 972, 947, 912, 848, 808, 756, 
739, 690, 638, 595, 580, 553 cm-1.  HRMS (ESI) Calculated for C24H24NO m/z (M+H) 
342.1858, Obsd. 342.1857. 
 
N-(4-methoxybenzyl)-N-methyl-1,4-diphenylbut-3-yn-2-amine 3.1c. To a 100 mL 
high-pressure tube containing a magnetic stir bar was added phenylacetaldehyde (2.23 g, 
18.3 mmol, 1.0 equiv), (4-methoxyphenyl)-N-methylmethanamine (PMB(Me)NH) (3.05 
g, 18.3 mmol, 1.1 equiv), phenylacetylene (2.06 g, 2.22 mL, 20.2 mmol, 1.1 equiv), 
oven-dried molecular sieves, (Grade 564, 3 Å, 8-12 mesh) (ca. 10 g) and toluene (40 
mL). The tube was then sealed and placed in a preheated 80 °C oil bath and was left to 
stir overnight.  The reaction tube was then removed from the oil bath and left to cool to rt. 
To the reaction mixture was added CuBr (0.263 g, 1.83 mmol, 0.1 equiv) and the tube 
resealed and returned to the 80 °C oil bath.  The reaction was allowed to proceed for 24 h 
at which time the high-pressure tube was removed from the oil bath and allowed to cool 
to rt. The crude reaction mixture was filtered through paper using a Buchner funnel and 
solids washed with EtOAc (100 mL).  The filtrate collected and added to a separatory 
funnel containing water (100 mL) and hexanes (100 mL).  The layers were separated and 
the organic layer washed with water (100 mL) and brine (100 mL).  The organic layer 
was then collected, dried over Na2SO4, filtered and then concentrated under reduced 
pressure.  Purification of the material was accomplished by flash column chromatography 
on a 6.5 × 15 cm column, eluting with 150 mL of hexanes followed by 2 L of 10% 







and then concentrated under reduced pressure to give propargylamine 3.1c (6.19 g, 94% 
yield) as a light yellow oil. Rf = 0.24 (15% EtOAc/hexanes).  1H NMR (CDCl3, 400 
MHz): δ 7.44-7.40 (m, 2H), 7.31-7.15 (m, 8H), 7.17 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.6 
Hz, 2H), 3.83 (dd, J = 8.3, 6.9 Hz, 1H), 3.77 (s, 3H), 3.70 (d, J = 13.0 Hz, 1H), 3.52 (d, J 
= 13.0 Hz, 1H), 3.05 (dd, J = 13.3, 6.9 Hz, 1H) 3.00 (dd, J = 13.4, 8.4 Hz, 1H), 2.34 (s, 
3H); 13C NMR (CDCl3, 125 MHz): δ 158.9, 139.0, 131.9, 131.3, 130.2, 129.6, 128.4, 
128.3, 128.1, 126.5, 123.6, 113.8, 87.0, 86.9, 58.9, 57.8, 55.4, 40.6, 38.0;  13C DEPT 
NMR (CDCl3, 125 MHz): δ CH3: 55.4, 38.0; CH2: 58.9, 40.6; CH1: 131.9, 130.2, 129.6, 
128.4, 128.3, 128.1, 126.5, 113.8, 57.8; CH0: 158.9, 139.0, 131.3, 123.6, 87.0, 86.9;  IR 
(neat): 3028, 2833, 1611, 1510, 1489, 1242, 1171, 1035, 756, 691 cm-1.  HRMS (ESI) 
Calculated for C25H26NO m/z (M+H) 356.2014, Obsd. 356.2008. 
 
1-(4-(benzyloxy)phenyl)-N-(4-methoxybenzyl)-4-(4-methoxyphenyl)-N-methylbut- 3-
yn-2-amine 3.1d. Obtained from the CuBr catalyzed 3-CC of 2-(4-(benzyloxy) 
phenyl)acetaldehyde, (4-methoxyphenyl)-N-methylmethanamine (PMB(Me)NH), and 1-
ethynyl-4-methoxybenzene to give propargylamine 3.1d as a yellow crystalline solid in 
98% yield. Rf = 0.22 (40% EtOAc/hexanes).  1H NMR (CDCl3, 400 MHz): δ 7.44-7.27 
(m, 7H), 7.18 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 
6.84-6.78 (m, 4H), 5.03 (s, 2H), 3.78-3.74 (m, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 3.68 (d, J 
= 13.0 Hz, 1H), 3.50 (d, J = 13.0 Hz, 1H), 2.98 (dd, J = 12.8, 6.2 Hz, 1H), 2.93 (dd, J = 
13.1, 8.1 Hz, 1H), 2.32 (s, 3H);  13C NMR (CDCl3, 125 MHz): δ 159.5, 158.8, 157.6, 






86.7, 85.5, 70.2, 58.9, 58.1, 55.5, 55.4, 39.8, 38.0;  13C DEPT NMR (CDCl3, 125 MHz): 
δ CH3: 55.5, 55.4, 38.0; CH2: 70.2, 58.9, 39.8; CH1: 133.3, 130.6, 130.3, 128.7, 128.1, 
127.7, 114.7, 114.1, 113.8, 58.1; CH0: 159.5, 158.8, 157.6, 137.4, 131.5, 131.4, 115.8, 
86.7, 85.5;  IR (neat): 2950, 2835, 1607, 1509, 1454, 1289, 1244, 1173, 1033, 831, 734, 
697 cm-1.  HRMS (ESI) Calculated for C33H34NO3 m/z (M+H) 492.2539, Obsd. 
492.2542. 
 
N-(4-methoxybenzyl)-N-(3-(4-methoxyphenyl)prop-2-yn-1-yl)cyanamide 3.2a. To a 
250 mL round-bottomed flask containing a magnetic stir bar was added propargylamine 
3.1a (5.030 g, 12.5 mmol, 1.0 equiv.), 3 M solution of CNBr in CH2Cl2 (8.40 mL, 25.1 
mmol, 2.0 equiv.), K2CO3 (3.916 g, 28.33 mmol, 2.3 equiv.), and dioxane (125 mL).  The 
reaction mixture was allowed to stir at rt for 24 h before being quenched with a saturated 
aqueous solution of NaHCO3 (25 mL). The reaction mixture was diluted in CH2Cl2 (100 
mL) and water (50 mL) and the layers separated.  The aqueous phase was extracted with 
CH2Cl2 (2 × 25 mL). The organic extract was then dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  Purification of the material was accomplished by 
flash column chromatography on a 5.7 × 15 cm column, eluting with 20% 
EtOAc/hexanes. The product containing fractions were combined and then concentrated 
under reduced pressure to give cyanamide 3.2a (3.608 g, 94% yield) as a light yellow oil. 
Rf = 0.40 (35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.40 (d, J = 9.0 Hz, 
2H), 7.31 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 4.26 (s, 






160.2, 133.6, 130.7, 126.0, 117.7, 114.5, 114.4, 114.3, 114.2, 87.2, 80.1, 55.6, 55.5, 54.3, 
41.1; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.6, 55.5; CH2: 54.3, 41.1; CH1: 
133.6, 130.7, 114.5, 114.3; CH0: 160.3, 160.2, 126.0, 117.7, 114.5, 114.4, 87.2, 80.1;  IR 
(neat): 2931, 2836, 1721, 1643, 1612, 1585, 1512, 1491, 1453, 1407, 1359, 1302, 1247, 
1223, 1175, 1145, 1107, 1078, 1034, 905 822, 758, 696 cm-1.  HRMS (ESI) Calculated 
for m/z C19H18N2NaO2 (M+Na) 329.1266, Obsd. 329.1263. 
 
N-benzyl-N-(3-phenylprop-2-ynyl)cyanamide 3.2b.  Cyanamide 3.2b was obtained as a 
light-yellow oil from the von Braun reaction of PMB propargylamine 3.1b in 90% yield. 
Rf = 0.23 (20% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.44-7.29 (m, 10H), 
4.31 (s, 2H), 3.93 (s, 2H);  13C NMR (CDCl3, 125 MHz): δ 134.0, 132.1, (2 × 129.2), (2 × 
129.1), 128.7, 122.1, 117.5, 87.4, 81.3, 54.8, 41.1;  13C DEPT NMR (CDCl3, 125 MHz): 
δ CH2: 54.8, 41.1; CH1: 132.1, (2 × 129.2), (2 × 129.1), 128.7; CH0: 134.0, 122.1, 117.5, 
87.4, 81.3;  IR (neat): 3032, 2212, 1720, 1598, 1489, 1455, 1442, 1339, 1258, 1107, 
1027, 1002, 966, 765, 734 cm-1.  HRMS (ESI) Calculated for C17H14N2Na m/z (M+Na) 
269.1055, Obsd. 269.1059. 
 
N-(1,4-diphenylbut-3-yn-2-yl)-N-methylcyanamide 3.2c.  Cyanamide 3.2c was 
obtained from the von Braun reaction of PMB propargylamine 3.1c as a light-yellow 











400 MHz): δ 7.43-7.39 (m, 2H), 7.36-7.25 (m, 8H), 4.10 (dd, J = 7.5, 7.5 Hz, 1H), 3.20 
(dd, J = 13.7, 7.5 Hz, 1H), 3.15 (dd, J = 13.7, 7.5 Hz, 1H), 2.89 (s, 3H);  13C NMR 
(CDCl3, 125 MHz): δ 136.1, 131.9, 129.5, 129.0, 128.8, 128.5, 127.4, 122.0, 116.8, 87.6, 
84.2, 56.6, 40.3, 37.7;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 37.7; CH2: 40.3; 
CH1: 131.9, 129.5, 129.0, 128.8, 128.5, 127.4, 56.6; CH0: 136.1, 122.0, 116.8, 87.6, 84.2;  
IR (neat): 3030, 2930, 2210, 1598, 1489, 1454, 1442, 1372, 1032, 723, 691 cm-1.  HRMS 
(ESI) Calculated for m/z C18H16N2Na (M+Na) 283.1211, Obsd. 283.1212. 
 
N-(1-(4-(benzyloxy)phenyl)-4-(4-methoxyphenyl)but-3-yn-2-yl)-N-methylcyanamide 
3.2d. Cyanamide 3.2d was obtained as a yellow crystalline solid from the von Braun 
reaction of PMB propargylamine 3.1d in 76% yield.  Rf = 0.41 (40% EtOAc/hexanes).  
1H NMR (CDCl3, 400 MHz): δ 7.44-7.32 (m, 5H), 7.35 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 
8.4 Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 5.05, (s, 2H), 4.04 (dd, J 
= 7.4, 7.4 Hz, 1H), 3.81 (s, 3H), 3.13 (dd, J = 13.7, 7.5 Hz, 1H), 3.09 (dd, J = 13.8, 7.4 
Hz, 1H), 2.90 (s, 3H);  13C NMR (CDCl3, 125 MHz): δ 160.2, 158.2, 137.2, 133.5, 130.7, 
128.8, 128.6, 128.1, 127.7, 117.0, 115.1, 114.2, 114.1, 87.6, 83.0, 70.2, 56.9, 55.5, 39.7, 
37.7;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.5, 37.7; CH2: 70.2, 39.7; CH1: 
133.5, 130.7, 128.8, 128.2, 127.7, 115.1, 114.2, 56.9; CH0: 160.2, 158.2, 137.2, 128.6, 
117.0, 114.1, 87.6, 83.0;  IR (neat): 3034, 2933, 2837, 2211, 1605, 1584, 1291, 1247, 
1174, 833, 740, 697 cm-1.  HRMS (ESI) Calculated for C26H24N2NaO2 m/z (M+Na) 







2-(ethylthio)-1,4-bis(4-methoxybenzyl)-1H-imidazole 3.3a.  To a 15 mL high-pressure 
tube containing a magnetic stir bar was added cyanamide 3.2a (0.1065 g, 0.347 mmol, 
1.0 equiv.), ethanethiol (0.2158 g, 260 mL, 3.47 mmol, 10.0 equiv.), iPr2EtN (0.6735 g, 
910 mL, 5.21 mmol, 15.0 equiv.) and isopropanol (2 mL).  The high-pressure tube was 
then sealed and placed in a preheated 120 °C oil bath.  After 24 h at 120 °C, the high-
pressure was removed from the oil bath and left to cool to rt. The crude reaction mixture 
was diluted in CH2Cl2 (50 mL) and water (50 mL) and the layers separated.  The aqueous 
phase was extracted with CH2Cl2 (2 × 25 mL).  The organic extract was then dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  Purification of the material 
was accomplished by flash column chromatography on a 2.5 × 15 cm column, eluting 
with 35% EtOAc/hexanes (with 3% Et3N).  The product containing fractions were 
combined and then concentrated under reduced pressure to give 2-thioimidazole 3.3a 
(0.0861 g, 67% yield) as a light yellow oil.  Rf = 0.24 (35% EtOAc/hexanes).  1H NMR 
(CDCl3, 500 MHz): δ 7.13 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 8.8 
Hz, 2H), 6.77 (d, J = 8.8 Hz, 2H) 6.42 (s, 1H), 4.96 (s, 2H), 3.80 (s, 2H), 3.73 (s, 6H), 
2.94 (q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.6 Hz, 3H);  13C NMR (CDCl3, 125 MHz): δ 159.3, 
158.0, 143.5, 140.5, 132.2, 130.0, 128.9, 128.7, 118.3, 114.3, 113.8, (2 × 55.4), 49.7, 
34.4, 29.5, 15.7;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: (2 × 55.4), 15.7; CH2: 
49.7, 34.4, 29.5; CH1: 130.0, 128.7, 118.3, 114.3, 113.8; CH0: 159.3, 158.0, 143.5, 140.5, 
132.2, 128.9;  IR (neat): 2931, 2834, 1612, 1584, 1512, 1453, 1300, 1247, 1176, 1106, 










1,4-dibenzyl-2-(ethylthio)-1H-imidazole 3.3b.  Obtained from the base catalyzed 
addition-cyclization-isomerization reaction of cyanamide 3.2b and ethanethiol to give 2-
thioimidazole 3.3b as a light-yellow oil in 77% yield. Rf = 0.38 (35% EtOAc/hexanes).  
1H NMR (CDCl3, 500 MHz): δ 7.33-7.18 (m, 8H), 7.11-7.10 (m, 2H), 6.50 (s, 1H), 5.09 
(s, 2H), 3.92 (s, 2H), 2.98 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H);  13C NMR 
(CDCl3, 125 MHz): δ 143.3, 141.0, 140.2, 137.0, 129.2, 129.0, 128.6, 128.1, 127.3, 
126.3, 118.7, 50.3, 35.5, 29.6, 15.2; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 15.2; 
CH2: 50.3, 35.5, 29.6; CH1: 129.2, 129.0, 128.6, 128.1, 127.3, 126.3, 118.7; CH0: 143.3, 
141.0, 140.2, 137.0;  IR (neat): 3028, 2928, 2362, 1676, 1603, 1559, 1495, 1453, 1419, 
1356, 1300, 1262, 1201, 1175, 1107, 1075, 1029, 732, 697, 668 cm-1. HRMS (ESI) 
Calculated for m/z C19H21N2S (M+H) 309.1425, Obsd. 309.1431. 
 
4,5-dibenzyl-2-(ethylthio)-1-methyl-1H-imidazole 3.3c.  Obtained from the base 
catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2c and ethanethiol 
to give 2-thioimidazole 3.3c as a light-yellow oil in 93% yield.  Rf = 0.46 (35% 
EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.26-7.14 (m, 8H), 6.96-6.95 (m, 4H), 
3.96 (s, 2H), 3.89 (s, 2H), 3.33 (s, 3H), 2.98 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H);  
13C NMR (CDCl3, 125 MHz): δ 140.9, 139.5, 139.0, 138.1, 128.8, 128.7, 128.4, 128.1, 













CH3: 31.4, 15.1; CH2: 33.9, 30.0, 29.5; CH1: 128.8, 128.7, 128.4, 128.1, 126.6, 125.9; 
CH0: 140.9, 139.5, 139.0, 138.1, 83.0;  IR (neat): 3060, 3026, 2965, 2926, 1602, 1494, 
1454, 1376, 1264, 1112, 1074, 1029, 739, 696 cm-1.  HRMS (ESI) Calculated for 
C20H23N2S m/z (M+H) 323.1582, Obsd. 323.1583. 
 
5-(4-(benzyloxy)benzyl)-2-(ethylthio) - 4 - (4-methoxybenzyl)-1-methyl-1H-imidazole 
3.3d. Obtained from the base catalyzed addition-cyclization-isomerization reaction of 
cyanamide 3.2d and ethanethiol to give 2-thioimidazole 3.3d as a light-yellow oil in 82% 
yield.  Rf = 0.35 (40% EtOAc/hexanes, with 1% Et3N).  1H NMR (CDCl3, 500 MHz): δ 
7.42-7.28 (m, 5H), 7.15 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 
2H), 6.76 (d, J = 8.8 Hz, 2H), 4.99 (s, 2H), 3.88 (s, 2H), 3.81 (s, 2H), 3.73 (s, 3H), 3.31 
(s, 3H), 2.95 (q, J = 7.6 Hz, 2H), 1.26 (t, J = 7.6 Hz, 3H);  13C NMR (CDCl3, 125 MHz): 
δ 157.9, 157.6, 139.4, 139.3, 137.1, 133.2, 130.5, 129.6, 129.1, 128.7, 128.1, 128.1, 
127.6, 115.1, 113.8, 70.2,  55.4, 33.1, 31.4, 29.5, 29.2, 15.1;   13C DEPT NMR (CDCl3,   
125 MHz): δ CH3: 55.4, 31.3, 15.1; CH2: 70.2, 33.1, 29.5, 29.2; CH1: 129.6, 129.1, 128.7, 
128.1, 127.6, 115.1, 113.8;  IR (neat): 2928, 2833, 1722, 1608, 1583, 1508, 1452, 1378, 
1240, 1173, 1026, 804, 734, 696 cm-1.  HRMS (ESI) Calculated for C28H31N2O2S m/z 















1,4-bis(4-methoxybenzyl)-2-(4-methoxybenzylthio)-1H-imidazole 3.4a.  Obtained 
from the base catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2a 
and (4-methoxyphenyl)methanethiol to give 2-thioimidazole 3.4a as a light-yellow oil in 
82% yield.  Rf = 0.19 (35% EtOAc/hexanes with 1% Et3N); 1H NMR (CDCl3, 500 MHz): 
δ 7.17 (d, J = 8.3 Hz, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 
8.8 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 6.74 (d, J = 8.8 Hz, 2H), 6.41 (s, 1H), 4.69, (s, 
2H), 4.10 (s, 2H), 3.85 (s, 2H), 3.76 (s, 3H), 3.76 (s, 3H), 3.74 (s, 3H);  13C NMR 
(CDCl3, 125 MHz): δ 159.3, 159.0, 158.1, 143.7, 139.7, 132.4, 130.2, 129.9, 128.8, 
128.8, 118.2, 114.2, 114.0, 113.8, 55.4, 55.4, 49.5, 39.9, 34.5;  13C DEPT NMR (CDCl3, 
125 MHz): δ CH3: 55.4, 55.4; CH2: 49.5, 39.9, 34.5; CH1: 130.2, 129.3, 128.8, 118.2, 
114.2, 114.0, 113.8; IR (neat): 2933, 2834, 1610, 1511, 1463, 1301, 1245, 1175, 1107, 
1033, 834, 795 cm-1.  HRMS (ESI) Calculated for C27H29N2O3S m/z (M+H) 461.1899, 
Obsd. 461.1899. 
 
1,4-dibenzyl-2-(4-methoxybenzylthio)-1H-imidazole 3.4b.  Obtained from the N,N-
diisopropylethylamine catalyzed addition reaction of cyanamide 3.2b and 4-
(methoxyphenyl)methanethiol to give 2-thioimidazole 3.4b as a light yellow oil in 71% 
yield. Rf = 0.26 (35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.31-7.18 (m, 
8H), 7.04 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 6.9 Hz, 1H), 6.90 (d, J = 6.9 Hz, 1H), 6.73 (d, 
J = 8.5 Hz, 2H), 6.46 (s, 1H), 4.78 (s, 2H) 4.10 (s, 2H), 3.93 (s, 2H), 3.78 (s, 3H);  13C 









128.5, 128.0, 127.4, 126.3, 118.6, 114.1, 55.5, 50.1, 40.0, 35.4; 13C DEPT NMR (CDCl3, 
125 MHz): δ CH3: 55.5; CH2: 50.1, 40.0, 35.4; CH1: 130.3, 129.1, 129.0, 128.5, 128.0, 
127.4, 126.3, 118.6, 114.1; CH0: 159.1, 143.4, 140.4, 140.1, 136.8 130.0;  IR (neat): 
3061, 3028, 2932, 2834, 1609, 1583, 1495, 1453, 1422, 1354, 1301, 1249, 1175, 1105, 
1074, 1031, 833, 731, 697, 660, 548 cm-1.  HRMS (ESI) Calculated for C25H25N2OS m/z 
(M+H) 401.1688, Obsd. 401.1693. 
 
4,5-dibenzyl-2-(4-methoxybenzylthio)-1-methyl-1H-imidazole 3.4c.  Obtained from 
the base catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2c and 4-
(methoxyphenyl)methanethiol to give 2-thioimidazole 3.4c as a light-yellow oil in 97% 
yield. Rf = 0.26 (35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.25-7.14 (m, 
8H), 6.92 (d, J = 8.8 Hz, 2H), 6.85 (m, 2H), 6.61 (d, J = 8.8 Hz, 2H), 4.00 (s, 2H), 3.97 
(s, 2H), 3.80 (s, 2H), 3.69 (s, 3H), 2.89 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 158.9, 
140.9, 139.6, 138.3, 138.0, 130.3, 130.1, (2 ´ 128.7), 128.4, 128.2, 128.1, 126.5, 126.0, 
113.8, 55.3, 40.3, 34.0, 31.1, 30.0; 13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.3, 
31.1; CH2: 40.3, 34.0, 30.0; CH1: 130.1, 128.7, 128.4, 128.1, 126.5, 126.0, 113.8; CH0: 
158.9, 140.9, 139.6, 138.3, 138.0, 130.3, 128.7, 128.2; IR (neat): 3028, 2932, 2835, 1706, 
1608, 1583, 1511, 1494, 1453, 1383, 1301, 1247, 1174, 1106, 1075, 1030, 912, 833, 728, 












1H-imidazole 3.4d.  Obtained from the base catalyzed addition-cyclization-isomerization 
reaction of cyanamide 3.2d and 4-(methoxyphenyl)methanethiol to give 2-thioimidazole 
3.4d as a light-yellow oil in 53% yield.  Rf = 0.10 (35% EtOAc/hexanes).  1H NMR 
(CDCl3, 500 MHz): δ 7.42-7.36 (m, 4H), 7.33-7.30 (m, 1H), 7.16 (d, J = 8.3 Hz, 2H), 
6.94 (d, J = 8.8 Hz, 2H), 6.80-6.75 (m, 4H) 6.63 (d, J = 8.3 Hz, 2H), 5.01 (s, 2H), 4.00 
(s, 2H), 3.90 (s, 2H), 3.76 (s, 3H), 3.75 (s, 2H), 3.70 (s, 3H), 2.90 (s, 3H);  13C NMR 
(CDCl3, 125 MHz): δ 158.9, 158.0, 157.6, 139.9, 138.1, 137.1, 133.2, 130.4, 130.3, 
130.1, 129.6, 129.1, 128.8, 128.5, 128.2, 127.7, 115.0, 114.1, 113.9, 113.8, 70.2, 55.4, 
55.3, 40.3, 33.1, 31.1, 29.2;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.4, 55.3, 
31.1; CH2: 70.2, 40.3, 33.1, 29.2; CH1: 130.1, 129.6, 129.1, 128.8, 128.2, 127.7, 115.0, 
113.9, 113.8; CH0: 158.9, 158.0, 157.6, 139.9, 138.1, 137.1, 133.2, 130.4, 130.3, 128.5, 
114.1;  IR (neat): 2932, 2835, 1703, 1608, 1583, 1509, 1453, 1381, 1301, 1239, 1174, 
1107, 1027, 918, 830, 733, 697, 653, 608 cm-1.  HRMS (ESI) Calculated for 
C34H35N2O3S m/z (M+H) 551.2368, Obsd. 551.2363. 
 
1,4-bis(4-methoxybenzyl)-2-(phenylthio)-1H-imidazole 3.5a.  Obtained from the base 














to give 2-thioimidazole 3.5a as a light-yellow oil in 83% yield.  Rf = 0.38 (35% 
EtOAc/hexanes with 1% Et3N).  1H NMR (CDCl3, 500 MHz): δ 7.25-7.17 (m, 4H), 7.16-
7.10 (m, 3H), 6.91 (d, J = 8.3 Hz, 2H), 6.82 (d, J = 8.3 Hz, 2H), 6.75 (d, J = 8.3 Hz, 2H), 
6.60 (s, 1H), 5.00 (s, 2H), 3.89 (s, 2H), 3.76 (s, 3H), 3.74 (s, 3H);  13C NMR (CDCl3, 125 
MHz): δ 159.4, 158.1, 144.4, 136.7, 135.7, 132.1, 130.0, 129.3, 129.1, 128.4, 127.9, 
126.5, 119.7, 114.2, 113.9, 55.4, 55.4, 50.3, 34.5;  13C DEPT NMR (CDCl3, 125 MHz): δ 
CH3: 55.4, 55.4; CH2: 50.3, 34.5; CH1: 130.0, 129.3, 129.1, 127.9, 126.5, 119.7, 114.2, 
113.9; CH0: 159.4, 158.1, 144.4, 136.7, 135.7, 132.1, 128.4;  IR (neat): 2932, 2835, 1721, 
1610, 1510, 1478, 1440, 1301, 1243, 1174, 1030, 736, 689 cm-1. HRMS (ESI) Calculated 
for C25H25N2O2S m/z (M+H) 417.1637, Obsd. 417.1632. 
 
1,4-dibenzyl-2-(phenylthio)-1H-imidazole 3.5b.  Obtained from the base catalyzed 
addition-cyclization-isomerization reaction of cyanamide 3.2b and thiophenol to give 2-
thioimidazole 3.5b as a light-yellow oil in 91% yield. Rf = 0.50 (35% EtOAc/hexanes).  
1H NMR (CDCl3, 500 MHz): δ 7.29 (d, J = 4.5 Hz, 4H), 7.26-7.21 (m, 6H), 7.17-7.14 
(m, 3H), 7.00-6.97 (m, 2H), 5.10 (s, 2H), 3.97 (s, 2H).  13C NMR (CDCl3, 125 MHz): δ 
144.1, 140.1, 136.4, 135.5, 131.7, 129.4, 129.1, 129.0, 128.6, 128.2, 128.1, 127.6, 126.7, 
126.4, 120.2, 50.9, 35.5;  13C DEPT NMR (CDCl3, 125 MHz): δ CH2: 50.9, 35.5; CH1: 
129.4, 129.1, 129.0, 128.6, 128.2, 128.1, 127.6, 126.7, 126.4, 120.2; CH0: 144.1, 140.1, 
136.4, 135.5, 131.7;  IR (neat): 3060, 3029, 1721, 1580, 1494, 1477, 1453, 1440, 1417, 
1344, 1302, 1234, 1155, 1121, 1080, 1024, 731 cm-1. HRMS (ESI) Calculated for 









4,5-dibenzyl-1-methyl-2-(phenylthio)-1H-imidazole 3.5c.  Obtained from the base 
catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2c and thiophenol 
to give 2-thioimidazole 3.5c as a light-yellow oil in 94% yield.  Rf = 0.36 (35% 
EtOAc/hexanes with 1% Et3N).  1H NMR (CDCl3, 500 MHz): δ 7.30-7.27 (m, 2H), 7.26-
7.09 (m, 9H), 7.07-7.04 (m, 2H), 6.95-6.91 (m, 2H), 4.02 (s, 2H), 3.92 (s, 2H), 3.26 (s, 
3H);  13C NMR (CDCl3, 125 MHz): δ 140.7, 140.3, 139.9, 137.7, 135.8, 129.8, 129.3, 
128.8, 128.7, 128.5, 128.0, 127.2, 126.7, 126.2, 126.1, 34.1, 31.7, 30.2;  13C NMR DEPT 
(CDCl3, 125 MHz): δ CH3: 31.7; CH2: 34.1, 30.2; CH1: 129.3, 128.8, 128.7, 128.5, 128.0, 
127.2, 126.7, 126.2, 126.1; CH0: 140.7, 140.3, 139.9, 137.7, 135.8;  IR (neat): 3059, 
3025, 2914, 1602, 1581, 1493, 1478, 1453, 1439, 1404, 1374, 1074, 1024, 736, 689 cm-1.  
HRMS (ESI) Calculated for C24H23N2S m/z (M+H) 371.1582, Obsd. 371.1581. 
 
5-(4-(benzyloxy)benzyl)-4-(4-methoxybenzyl)-1-methyl-2-(phenylthio)-1H-imidazole 
3.5d.  Obtained from the base catalyzed addition-cyclization-isomerization reaction of 
cyanamide 3.2d and thiophenol to give 2-thioimidazole 3.5d as a light-yellow oil in 87% 
yield.  Rf = 0.32 (35% EtOAc/hexanes with 1% Et3N).  1H NMR (CDCl3, 500 MHz): δ 
7.42-7.34 (m, 4H), 7.33-7.28 (m, 1H), 7.23-7.17 (m, 4H), 7.13-7.09 (m, 1H), 7.06-7.03 
(m, 2H), 6.86-6.81 (m, 4H), 6.80-6.77 (m, 2H), 5.00 (s, 2H), 3.94 (s, 2H), 3.85 (s, 2H), 













136.1, 135.6, 132.9, 130.3, 130.0, 129.6, 129.3, 129.0, 128.7, 128.1, 127.6, 127.2, 126.2, 
115.2, 113.9, 70.2, 55.4, 33.2, 31.7, 29.4;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 
55.4, 31.7; CH2: 70.2, 33.2, 29.4; CH1: 129.6, 129.3, 129.0, 128.7, 128.1, 127.6, 127.2, 
126.2, 115.2, 113.9; CH0: 158.0, 157.6, 140.5, 137.1, 136.1, 135.6, 132.9, 130.3, 130.0;  
IR (neat): 3031, 2907, 2833, 1609, 1582, 1508, 1478, 1378, 1240, 1173, 1024, 804, 735, 
691 cm-1.  HRMS (ESI) Calculated for C32H31N2O2S m/z (M+H) 507.2106, Obsd. 
507.2110. 
 
4-(1,4-bis(4-methoxybenzyl)-1H-imidazol-2-ylthio)phenol 3.6a.  Obtained from the 
base catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2a and 4-
mercaptophenol to give 2-thioimidazole 3.6a as a light-yellow oil in 74% yield. Rf  = 0.06 
(35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.12-7.11 (m, 4H), 6.95 (d, J = 
8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 6.78 (d, J = 8.8 Hz, 2H), 6.53 (s, 1H), 6.29 (d, J = 
8.8 Hz, 2H), 5.17 (s, 2H), 3.81 (s, 3H), 3.75 (s, 3H);  13C NMR (CDCl3, 125 MHz): δ 
158.6, 158.2, 143.3, 134.2, 131.4, 130.0, 129.0, 128.3, 118.3, 117.0, 114.4, 113.9, 55.4, 
55.3, 50.2, 33.7;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.4, 55.3; CH2: 50.2, 
33.7; CH1: 134.2, 130.0, 129.0, 117.0, 114.4, 113.9; CH0: 158.6, 158.2, 143.3, 131.4, 
128.3, 118.3;  IR (neat): 2931, 2836, 2001, 1612, 1583, 1513, 1495, 1442, 1356, 1247, 

















4-(1,4-dibenzyl-1H-imidazol-2-ylthio)phenol 3.6b.  Obtained from the base catalyzed 
addition-cyclization-isomerization reaction of cyanamide 3.2b and 4-mercaptophenol to 
give 2-thioimidazole 3.6b as a light-yellow oil in 64% yield. Rf = 0.12 (35% 
EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.38-7.31 (m, 3H), 7.26-7.16 (m, 8H), 
6.97 (d, J = 8.8 Hz, 2H), 6.59 (s, 1H), 6.34 (d, J = 8.8 Hz, 2H), 5.26 (s, 2H), 3.91 (s, 2H);   
13C NMR (CDCl3, 125 MHz): δ 159.0, 142.9, 142.3, 139.4, 136.4, 134.4, (2 × 129.2), 
128.7, 128.4, 127.6, 126.5, 119.7, 118.8, 117.2, 50.8, 34.7;  13C DEPT NMR (CDCl3, 125 
MHz): δ CH2: 50.8, 34.7; CH1: 134.4, (2 × 129.2), 128.7, 128.4, 127.6, 126.5, 118.8, 
117.2; CH0: 159.0, 142.9, 142.3, 139.4, 136.4, 119.7;  IR (neat): 3061, 3029, 2780, 2655, 
1599, 1580, 1453, 1418, 1359, 1273, 1236, 1168, 830, 732, 697 cm-1.  HRMS (ESI) 
Calculated for C23H21N2OS m/z (M+H) 373.1357, Obsd. 373.1374. 
 
4-(4,5-dibenzyl-1-methyl-1H-imidazol-2-ylthio)phenol 3.6c.  Obtained from the base 
catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2c and 4-
mercaptophenol to give 2-thioimidazole 3.6c as a light-yellow oil in 77% yield. Rf = 0.15 
(35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.25-7.18 (m, 8H), 6.97 (dd, J = 
7.3, 4.0 Hz, 2H), 6.94-6.92 (m, 2H), 6.33 (d, J = 8.3 Hz, 2H), 3.96 (s, 2H), 3.95 (s, 2H), 
3.46 (s, 3H);  13C NMR (CDCl3, 125 MHz): δ 158.1, 140.2, 139.2, 137.7, 133.2, 129.0, 
128.8, 128.6, 128.1, 126.9, 126.3, 117.0, 33.5, 32.0, 30.2;  13C DEPT NMR (CDCl3, 125 
MHz): δ CH3: 32.0; CH2: 33.5, 30.2; CH1: 133.2, 129.0, 128.8, 128.6, 128.1, 126.9, 
126.3, 117.0; CH0: 158.1, 140.2, 139.2, 137.7;  IR (neat): 3059, 3026, 2920, 1722, 1639, 









for C24H23N2OS m/z (M+H) 387.1531, Obsd. 387.1531. 
 
4 - (5 - (4 - (benzyloxy)benzyl) - 4 - (4 - methoxybenzyl) - 1-methyl - 1H - imidazol-2-
ylthio)phenol 3.6d.  Obtained from the base catalyzed addition-cyclization-isomerization 
reaction of cyanamide 3.2d and 4-mercaptophenol to give 2-thioimidazole 3.6d as a light-
yellow oil in 78% yield.  Rf = 0.06 (35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): 
δ 7.44-7.33 (m, 5H), 7.08 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.88 (s, 4H), 6.71 
(d, J = 8.8 Hz, 2H), 6.30 (d, J = 8.8 Hz, 2H), 5.04 (s, 2H), 3.90 (s, 2H), 3.87 (s, 2H), 3.71 
(s, 3H), 3.47 (s, 3H);  13C NMR (CDCl3, 125 MHz): δ 158.3, 158.1, 157.8, 140.4, 139.3, 
137.1, 133.3, 132.4, 130.0, 129.7, 129.2, 128.8, 128.7, 128.2, 127.7, 120.8, 117.0, 115.3, 
114.0, 70.3, 55.5, 32.6, 32.0, 29.3;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 55.5, 
32.0; CH2: 70.3, 32.6, 29.3; CH1: 133.3, 129.7, 129.2, 128.8, 128.7, 127.7, 117.0, 115.3, 
114.0; CH0: 158.3, 158.1, 157.8, 140.4, 139.3, 137.1, 132.4, 130.0, 128.2, 120.8;  IR 
(neat): 2926, 2160, 1610, 1582, 1510, 1495, 1452, 1381, 1274, 1245, 1175, 1118, 1034, 












1,4-bis((1,4-dibenzyl-1H-imidazol-2-ylthio)methyl)benzene 3.7a.  Obtained from the 
base catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2b and 1,4-
phenylenedimethanethiol to give 2-thioimidazole 3.7b as a light-yellow oil in 71% yield.  
Rf = 0.16 (35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 7.32-7.18 (m, 16H), 
7.00 (s, 4H), 6.93 (d, J = 8.0 Hz, 2H), 6.92 (d, J = 6.5 Hz, 2H), 6.47 (s, 2H), 4.75 (s, 4H), 
4.11 (s, 4H), 3.93 (s, 4H);  13C NMR (CDCl3, 125 MHz): δ 143.3, 140.1, 139.8, 136.9, 
136.5, 129.2, (2 × 129.0), 128.5, 128.0, 127.2, 126.2, 118.7, 50.0, 40.0, 35.2;  13C DEPT 
NMR (CDCl3, 125 MHz): δ CH2: 50.0, 40.0, 35.2; CH1: 136.5, 129.2, (2 × 129.0), 128.5, 
128.0, 127.2, 126.2, 118.7; CH0: 143.3, 140.1, 139.8, 136.9, 136.5;  IR (neat): 3061, 
3027, 2926, 1603, 1558, 1511, 1495, 1453, 1420, 1355, 1299, 1241, 1201, 1104, 1074, 
















1,4-bis((4,5-dibenzyl-1-methyl-1H-imidazol-2-ylthio)methyl)benzene 3.7b.  Obtained 
from the base catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2c 
and 1,4-benzene dimethanethiol to give 2-thioimidazole 3.7a as a colorless crystalline 
solid in 73% yield.  Rf = 0.11 (35% EtOAc/hexanes).  1H NMR (CDCl3, 500 MHz): δ 
7.20-7.08 (m, 16H), 6.80 (d, J = 6.0 Hz, 4H), 6.69 (s, 4H); 3.92 (s, 4H), 3.88 (s, 4H), 3.74 
(s, 4H), 2.77 (s, 6H);  13C NMR (CDCl3, 125 MHz): δ 141.0, 139.7, 138.1, 137.3, 129.0, 
(2 × 128.8), 128.5, 128.2, 126.8, 126.1, 40.5, 34.1, 31.1, 30.2;  13C DEPT NMR (CDCl3, 
125 MHz): δ CH3: 31.1; CH2: 40.5, 34.1, 30.2; CH1: 129.0, (2 × 128.8), 128.5, 128.2, 
126.8, 126.1; CH0: 141.0, 139.7, 138.1, 137.3;  IR (neat): 3026, 2917, 2848, 2182, 1969, 
1599, 1582, 1494, 1460, 1452, 1433, 1275, 1244, 826, 743, 726, 696 cm-1. HRMS (ESI) 
Calculated for C44H43N4S2 m/z (M+H) 691.2929, Obsd. 691.2936. 
 
1,4-bis(4-methoxybenzyl)-2-phenoxy-1H-imidazole 3.8a.  In a 15 mL high-pressure 
tube containing a magnetic stir bar was added cyanamide 3.2a (0.1201 g, 0.392 mmol, 








equiv.) and toluene (1.5 mL).  The high-pressure tube was then sealed and placed in a 
preheated 150 °C oil bath.  After 24 h at 150 °C, the high-pressure was removed from the 
oil bath and left to cool to rt.  The crude reaction mixture was diluted in CH2Cl2 (50 mL) 
and water (50 mL) and the layers separated.  The aqueous phase was extracted with 
CH2Cl2 (2 × 25 mL).  The organic extract was then dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  Purification of the material was accomplished by 
flash column chromatography on a 2.5 × 15 cm column, eluting with 350 mL of 25% 
EtOAc/hexanes (with 1% Et3N).  The product containing fractions were combined and 
then concentrated under reduced pressure to give 2-oxoimidazole 3.8a (0.1206 g, 77% 
yield) as a light yellow oil. Rf = 0.43 (40% EtOAc/hexane with 1% Et3N).  1H NMR 
(CDCl3, 500 MHz): δ 7.32 (dd, J = 7.3, 8.8 Hz, 2H), 7.20-7.14 (m, 4H), 7.13-7.07 (m, 
3H), 6.84-6.81 (m, 4H), 6.13 (s, 1H), 4.82 (s, 2H), 3.77 (s, 3H), 3.77 (s, 3H), 3.76 (s, 2H);  
13C NMR (CDCl3, 125 MHz): δ 159.4, 158.1, 155.7, 148.8, 137.9, 132.1, 130.1, 129.8, 
129.1, 128.7, 124.1, 118.1, 114.3, 113.9, 112.3, 55.4, 55.4, 47.8, 34.7;  13C DEPT NMR 
(CDCl3, 125 MHz): δ CH3: 55.4, 55.4; CH2: 47.8, 34.7; CH1: 130.1, 129.8, 129.1, 124.1, 
118.1, 114.3, 113.9, 112.3;  IR (neat): 2933, 2834, 1611, 1587, 1509, 1476, 1299, 1240, 
1204, 1174, 1030, 807, 755, 687 cm-1. HRMS (ESI) Calculated for C25H25N2O3 m/z 
(M+H) 401.1865, Obsd. 401.1860. 
 
4,5-dibenzyl-1-methyl-2-phenoxy-1H-imidazole 3.8b.  Obtained from the base 
catalyzed addition-cyclization-isomerization reaction of cyanamide 3.2c and phenol to 








acetone/hexane).  1H NMR (CDCl3, 500 MHz): δ 7.33-7.12 (m, 11H), 7.10-7.06 (m, 2H), 
7.05-7.02 (m, 2H), 3.91 (s, 2H), 3.88 (s, 2H), 3.14 (s, 3H); 13C NMR (CDCl3, 125 MHz): 
δ 156.0, 148.2, 141.1, 138.5, 133.1, 129.8, 128.8, 128.7, 128.4, 128.1, 126.6, 126.0, 
123.8, 122.3, 117.4, 33.8, 29.7, 29.2;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 29.2; 
CH2: 33.8, 29.7; CH1: 129.8, 128.8, 128.7, 128.4, 128.1, 126.6, 126.0, 123.8, 117.4; CH0: 
156.0, 148.2, 141.1, 138.5, 133.1, 122.3;  IR (neat): 3060, 3026, 2910, 1593, 1520, 1482, 
1453, 1408, 1237, 1209, 1159, 1073, 1027, 750, 726, 695 cm-1.  HRMS (ESI) Calculated 
for C24H23N2O m/z (M+H) 355.1810, Obsd. 355.1807. 
 
5 - (4 - (benzyloxy)benzyl) - 4 - (4 - methoxybenzyl) - 1 - methyl - 2 - phenoxy - 1H - 
imidazole 3.8c. Obtained from the base catalyzed addition-cyclization-isomerization 
reaction of cyanamide 3.2d and phenol to give 2-oxoimidazole 3.8c, as a light-yellow oil 
in 62% yield. Rf = 0.48 (40% EtOAc/hexane with 1% Et3N).  1H NMR (CDCl3, 500 
MHz): δ 7.42 (d, J = 7.5 Hz, 2H), 7.37 (t, J = 9.0 Hz, 2H), 7.34-7.30 (m, 3H), 7.18 (d, J = 
8.0 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 7.5 Hz, 2H), 
6.87 (d, J = 7.5 Hz, 2H), 6.79 (d, J = 9.5 Hz, 2H), 5.03 (s, 2H), 3.82 (s, 2H), 3.83 (s, 2H), 
3.77 (s, 3H), 3.16 (s, 3H);  13C NMR (CDCl3, 125 MHz): δ 158.0, 157.7, 156.1, 148.2, 
137.2, 133.4, 133.3, 130.9, 129.8, 129.7, 129.2, 128.8, 128.2, 127.7, 123.8, 122.5, 117.5, 
115.2, 113.9, 70.3, 55.5, 33.0, 29.3, 28.9;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 
55.5, 29.3; CH2: 70.3, 33.0, 28.9; CH1: 129.8, 129.7, 129.2, 128.8, 128.2, 127.7, 123.8, 








IR (neat): 3032, 2932, 1609, 1509, 1486, 1242, 1026, 754 cm-1.  HRMS (ESI) Calculated 
for C32H31N2O3 m/z (M+H) 491.2335, Obsd. 491.2329. 
 
4,5-dibenzyl-2-methoxy-1-methyl-1H-imidazole 3.9a.  In a 15 mL high-pressure tube 
containing a magnetic stir bar was added cyanamide 3.2c (0.113 g, 0.435 mmol, 1.0 
equiv.), K2CO3 (0.601 g, 4.35 mmol, 10.0 equiv.) and methanol (4.0 mL).  The high-
pressure tube was then sealed and placed in a preheated 150 °C oil bath.  After 24 h at 
150 °C, the high-pressure was removed from the oil bath and left to cool to rt. The crude 
reaction mixture was diluted in CH2Cl2 (50 mL) and water (50 mL) and the layers 
separated.  The aqueous phase was extracted with CH2Cl2 (2 × 25 mL).  The organic 
extract was then dried over Na2SO4, filtered, and concentrated under reduced pressure.  
Purification of the material was accomplished by flash column chromatography on a 2.5 
× 15 cm column, eluting with 400 mL of 20% EtOAc/hexanes (with 1% Et3N).  The 
product containing fractions were combined and then concentrated under reduced 
pressure to give 2-oxoimidazole 3.9a (0.1041 g, 82% yield) as a light yellow oil.  Rf = 
0.18 (35% EtOAc/hexane, 1% Et3N).  1H NMR (CDCl3, 500 MHz): δ 7.28-7.18 (m, 6H), 
7.17-7.11 (m, 2H), 7.03-7.00 (m, 2H), 3.99 (s, 3H), 3.88 (s, 2H), 3.81 (s, 2H), 3.02 (s, 
3H);  13C NMR (CDCl3, 125 MHz): δ 152.5, 141.3, 138.9, 131.4, 128.6, 128.6, 128.3, 
128.1, 126.4, 125.9, 121.2, 56.4, 33.7, 29.6, 28.4; 13C DEPT NMR (CDCl3, 125 MHz): δ 
CH3: 56.4, 28.4; CH2: 33.7, 29.6; CH1: 128.6, 128.6, 128.3, 128.1, 126.4, 125.9; CH0: 
152.5, 141.3, 138.9, 131.4, 121.2; IR (neat): 3025, 2940, 1602, 1547, 1505, 1493, 1452, 








m/z (M+H) 293.1654, Obsd. 293.1650. 
 
4,5-dibenzyl-2-isopropoxy-1-methyl-1H-imidazole 3.9b.  In a 15 mL high-pressure 
tube containing a magnetic stir bar was added cyanamide 3.2c (0.1030 g, 0.396 mmol, 1.0 
equiv.), K2CO3 (0.5468 g, 3.96 mmol, 10.0 equiv.) and methanol (4.0 mL).  The high-
pressure tube was then sealed and placed in a preheated 150 °C oil bath.  After 24 h at 
150 °C, the high-pressure was removed from the oil bath and left to cool to rt. The crude 
reaction mixture was diluted in CH2Cl2 (50 mL) and water (50 mL) and the layers 
separated.  The aqueous phase was extracted with CH2Cl2 (2 × 25 mL).  The organic 
extract was then dried over Na2SO4, filtered, and concentrated under reduced pressure.  
Purification of the material was accomplished by flash column chromatography on a 2.5 ´ 
15 cm column, eluting with 300 mL of 20% EtOAc/hexanes (with 1% Et3N).  The 
product containing fractions were combined and then concentrated under reduced 
pressure to give 2-oxoimidazole 3.9b (0.0854 g, 67% yield) as a light yellow oil. Rf = 
0.45 (35% EtOAc/hexane, 1% Et3N).  1H NMR (CDCl3, 500 MHz): δ 7.27-7.24 (m, 2H), 
7.23-7.18 (m, 4H), 7.17-7.10 (m, 2H), 7.03-6.99 (m, 2H), 5.09 (sept, J = 6.2 Hz, 1H), 
3.87 (s, 2H), 3.79 (s, 2H), 3.01 (s, 3H), 1.33 (d, J = 6.4 Hz, 6H);  13C NMR (CDCl3, 125 
MHz): δ 151.5, 141.5, 139.1, 131.4, (2 × 128.6) 128.3, 128.2, 126.4, 125.8, 120.6, 72.5, 
33.7, 29.6, 28.4, 22.4;  13C DEPT NMR (CDCl3, 125 MHz): δ CH3: 28.4, 22.4; CH2: 
33.7, 29.6; CH1: (2 × 128.6), 128.3, 128.2, 126.4, 125.8, 72.5; CH0: 151.5, 141.5, 139.1, 










1409, 1383, 1108, 975, 724, 695 cm-1.  HRMS (ESI) Calculated for C21H25N2O m/z 



























































































































































Coupling Partners 3o Amine Cyanamide







































































































































































































































































































































































































































































































































3.2b, R1 = Bn, R2 = H, R3 = Ph
3.2c, R1 = Me, R2 = Bn, R3 = Ph
3.7a, R1 = Bn, R2 = H, R3 = Ph (71%)
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